documents incorporated reference parts portions registrants proxy statement annual meeting shareholders filed within days close iii registrants fiscal year proxy statement incorporated reference report reportitem part business general segments business geographic areas raw materials patents trademarks seasonality competition environment regulation employees human capital management available information risk factors b unresolved staff comments properties legal proceedings mine safety disclosures executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities reserved managements discussion analysis results operations financial condition quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accountant fees services part iv exhibits financial statement schedules summary signatures exhibit index cautionary note regarding forwardlooking statements annual report johnson johnson 's publicly available documents contain forwardlooking statements within meaning safe harbor provisions us private securities litigation reform act management representatives johnson johnson subsidiaries company also may time time make forwardlooking statements forwardlooking statements relate strictly historical current facts reflect managements assumptions views plans objectives projections future forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations expected operating results financial performance impact planned acquisitions dispositions companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current beliefs expectations assumptions regarding future events subject uncertainties risks changes difficult predict many outside company 's control investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize companys actual results financial condition could vary materially expectations projections expressed implied forwardlooking statements investors therefore cautioned rely forwardlooking statements risks uncertainties include limited risks related product development market success competition challenges uncertainties inherent innovation development new improved products technologies companys continued growth success depend including uncertainty clinical outcomes additional analysis existing clinical data obtaining regulatory approvals health plan coverage customer access initial continued commercial success challenges companys ability obtain protect adequate patent intellectual property rights new existing products technologies united states important markets impact patent expirations typically followed introduction competing biosimilars generics resulting revenue market share losses increasingly aggressive frequent challenges companys patents competitors others seeking launch competing generic biosimilar products increased receptivity courts united states patent trademark office decision makers challenges potentially resulting loss market exclusivity rapid decline sales relevant product sooner expected competition research development new improved products processes technologies result product process obsolescence competition reach agreement third parties collaboration licensing development marketing agreements products technologies competition based costeffectiveness product performance technological advances patents attained competitors allegations companys products infringe patents intellectual property rights third parties could adversely affect companys ability sell products question require payment money damages future royalties risks related product liability litigation regulatory activity product efficacy safety concerns whether based scientific evidence potentially resulting product withdrawals recalls regulatory action part united states food drug administration international counterparts declining sales reputational damage increased litigation expense share price impact impact including declining sales reputational damage significant litigation government action adverse company including product liability claims allegations related pharmaceutical marketing practices contracting strategies impact adverse judgment settlement adequacy reserves related legal proceedings including patent litigation product liability personal injury claims securities class actions government investigations employment legal proceedings increased scrutiny health care industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business failure meet compliance obligations mcneilppc inc consent decree compliance agreements governments government agencies could result significant sanctions potential changes applicable laws regulations affecting united states international operations including relating approval new products licensing patent rights sales promotion health care products access reimbursement pricing health care products services environmental protection sourcing raw materials compliance local regulations laws may restrict companys ability manufacture sell products relevant markets including requirements comply medical device reporting regulations requirements european union 's medical devices regulation changes domestic international tax laws regulations including changes related tax cuts jobs act united states increasing audit scrutiny tax authorities around world exposures additional tax liabilities potentially excess existing reserves issuance new revised accounting standards financial accounting standards board regulations securities exchange commission risks related companys strategic initiatives healthcare market trends pricing pressures resulting trends toward health care cost containment including continued consolidation among health care providers market participants trends toward managed care shift toward governments increasingly becoming primary payers health care expenses significant new entrants health care markets seeking reduce costs government pressure companies voluntarily reduce costs price increases restricted spending patterns individual institutional governmental purchasers health care products services due economic hardship budgetary constraints challenges companys ability realize strategy growth including externally sourced innovations development collaborations strategic acquisitions licensing marketing agreements potential heightened costs external arrangements due competitive pressures potential expected strategic benefits opportunities planned completed acquisition divestiture company may realized may take longer realize expected potential expected benefits opportunities related past ongoing restructuring actions may realized may take longer realize expected risks related economic conditions financial markets operating internationally risks associated global operations company customers suppliers including foreign governments countries company operates impact inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins potential changes exportimport trade laws regulations policies united states countries including increased trade restrictions tariffs potential drug reimportation legislation impact international operations financial instability international economies sovereign risk possible imposition governmental controls restrictive economic policies unstable international governments legal systems impact global public health crises pandemics including outbreak novel coronavirus covid pandemic changes global climate extreme weather natural disasters could affect demand company 's products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity company 's products operations impact armed conflicts terrorist attacks united states parts world including social economic disruptions instability financial marketsrisks related supply chain operations difficulties delays manufacturing internally third party providers otherwise within supply chain may lead voluntary involuntary business interruptions shutdowns product shortages withdrawals suspensions products market potential regulatory action interruptions breaches company 's information technology systems company 's vendors could result reputational competitive operational business harm well financial costs regulatory action reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect supply sourcing pricing materials used companys products potential expected benefits opportunities related restructuring actions contemplated global supply chain including company 's transaction jabil may realized may take longer realize expected including due required approvals applicable regulatory authorities disruptions associated announced global supply chain actions may adversely affect supply sourcing materials used company 's products investors also carefully read risk factors described item annual report description certain risks could among things cause companys actual results differ materially expressed forwardlooking statements investors understand possible predict identify factors consider risks described item complete statement potential risks uncertainties company undertake publicly update forwardlooking statement may made time time whether result new information future events developmentspart item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities company 's three business segments consumer health previously referred consumer pharmaceutical medical devices within strategic parameters provided committee senior management groups us international operating companies responsible strategic plans daytoday operations companies subsidiary within business segments limited exceptions managed residents country located segments business company organized three business segments consumer health pharmaceutical medical devices additional information required item incorporated herein reference narrative tabular descriptions segments operating results item managements discussion analysis results operations financial condition report note segments business geographic areas notes consolidated financial statements included item report consumer health consumer health segment includes broad range products focused personal healthcare used skin healthbeauty overthecounter medicines baby care oral care womens health wound care markets major brands skin healthbeauty include aveeno clean clear dr cilabo neutrogena ogx product lines overthecounter otc medicines include broad family tylenol acetaminophen products sudafed cold flu allergy products benadryl zyrtec allergy products motrin ib ibuprofen products nicorette smoking cessation products outside us zarbees naturals pepcid line acid reflux products baby care includes johnsons aveeno baby line products oral care includes listerine product line major brands womens health outside north america stayfree carefree sanitary pads ob tampon brands wound care brands include bandaid brand adhesive bandages neosporin first aid product lines products marketed general public sold online ecommerce retail outlets distributors throughout world pharmaceutical pharmaceutical segment focused six therapeutic areas immunology eg rheumatoid arthritis inflammatory bowel disease psoriasis infectious diseases eg hivaids neuroscience eg mood disorders neurodegenerative disorders schizophrenia oncology eg prostate cancer hematologic malignancies cardiovascular metabolism eg thrombosis diabetes pulmonary hypertension eg pulmonary arterial hypertension medicines segment distributed directly retailers wholesalers hospitals health care professionals prescription use key products pharmaceutical segment include remicade infliximab treatment number immunemediated inflammatory diseases simponi golimumab subcutaneous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis stelara ustekinumab treatment adults children moderate severe plaque psoriasis adults active psoriatic arthritis adults moderately severely active crohn 's disease treatment moderately severely active ulcerative colitis tremfya guselkumab treatment adults moderate severe plaque psoriasis edurant rilpivirine prezista darunavir prezcobix rezolsta darunavircobicistat antiretroviral medicines treatment human immunodeficiency virus hiv combination antiretroviral products symtuza darunavircobicistatemtricitabinetenofovir alafenamide oncedaily single tablet regimen treatment hiv concerta methylphenidate hcl extendedrelease tablets cii treatment attention deficit hyperactivity disorder invega sustenna xeplion paliperidone palmitate treatment schizophrenia andschizoaffective disorder adults invega trinza trevicta paliperidone palmitate treatment schizophrenia patients adequately treated invega sustenna least four months risperdal consta risperidone longacting injection treatment schizophrenia maintenance treatment bipolar disorder adults zytiga abiraterone acetate treatment metastatic castration resistant prostate cancer crpc metastatic highrisk castrationsensitive prostate cancer imbruvica ibrutinib treatment certain bcell malignancies blood cancers chronic graft versus host disease waldenstrm 's macroglobulinemia darzalex daratumumab treatment relapsedrefractory multiple myeloma erleada apalutamide nextgeneration androgen receptor inhibitor treatment patients prostate cancer velcade bortezomib treatment multiple myeloma mantle cell lymphoma procrit eprex epoetin alfa treatment chemotherapyinduced anemia patients chronic kidney disease xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt may lead pulmonary embolism pe patients undergoing hip knee replacement surgery reduce risk stroke systemic embolism patients nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe invokana canagliflozin treatment adults type diabetes invokamet vokanamet canagliflozinmetformin hcl combination therapy fixed doses canagliflozin metformin hydrochloride treatment adults type diabetes invokamet xr canagliflozinmetformin hydrochloride extendedrelease oncedaily fixeddose combination therapy canagliflozin metformin hydrochloride extendedrelease treatment adults type diabetes opsumit macitentan monotherapy combination indicated longterm treatment pulmonary arterial hypertension pah uptravi selexipag approved oral selective ip receptor agonist targeting prostacyclin pathway pah many medicines developed collaboration strategic partners licensed companies maintain active lifecycle development programs medical devices medical devices segment includes broad range products used interventional solutions orthopaedics surgery vision fields medical devices interventional solutions include electrophysiology products biosense webster treat cardiovascular diseases neurovascular care cerenovus treats hemorrhagic ischemic stroke orthopaedics portfolio depuy synthes comprised products support hips knees trauma spine sports surgery portfolios ethicon include advanced general surgery offerings solutions focus breast aesthetics mentor ear nose throat acclarent procedures johnson johnson vision products acuvue brand disposable contact lenses ophthalmic products related cataract laser refractive surgery products distributed wholesalers hospitals retailers used predominantly professional fields physicians nurses hospitals eye care professionals clinics geographic areas johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing products made sold international business include many described segments business consumer health pharmaceutical medical devices however principal markets products methods distribution international business vary country culture products sold international business include developed us subsidiaries abroad investments activities countries outside us subject higher risks comparable us activities investment commercial climate may influenced financial instability international economies restrictive economic policies political legal system uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents company 's subsidiaries made practice obtaining patent protection products processes possible licensed significant number patents us countries relating products product uses formulations manufacturing processes aggregate believed material importance company operation businesses companys subsidiaries face patent challenges third parties including challenges seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products significant legal proceedings claims involving company 's patent intellectual property described note legal proceedingsintellectual property notes consolidated financial statements included item report sales companys largest product stelara ustekinumab accounted approximately company 's total revenues fiscal accordingly patents related product believed material company janssen biotech inc whollyowned subsidiary johnson johnson owns patents specifically related stelara latest expiring united states patent expires latest expiring european patent expires sales companys second largest product darzalex daratumumab darzalex faspro daratumumab hyaluronidasefihj accounted approximately company 's total revenues fiscal accordingly patents related product believed material company genmab owns patents related darzalex janssen biotech inc exclusive license patents latest expiring licensed united states patent expires latest expiring licensed european patent expires janssen biotech inc owns separate patent portfolio related darzalex faspro sales companys third largest product imbruvica ibrutinib accounted approximately company 's total revenues fiscal accordingly patents related product believed material company pharmacyclics llc abbvie company owns patents related imbruvica janssen biotech inc exclusive license patents pharmacyclics patents expiration dates listed approved drug products therapeutic equivalence evaluations orange book pharmacyclics llc janssen biotech inc entered confidential settlement agreements certain generic companies granting licenses market generic ibrutinib products united states expiration certain patents trademarks companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration us countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines company 's subsidiaries compete companies locally globally competition exists product lines without regard number size competing companies involved competition research internally externally sourced involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property companys product portfolio important company 's success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involve significant expenditures advertising promotion environment company subject variety us international environmental protection measures company believes operations comply material respects applicable environmental laws regulations companys compliance requirements change past year expected material effect upon capital expenditures cash flows earnings competitive position regulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation enforcement company subject costly complex us foreign laws governmental regulations adverse regulatory action may materially adversely affect company 's financial condition business operations us drug device cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration us fda continues result increases amounts testing documentation required us fda approval new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside us new medical device regulatory framework new privacy regulations europe countries examples increased regulation regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases companys subsidiaries may deem advisable initiate product recalls us fda regulatory agencies around globe also increasing enforcement activities us fda conclude compliance applicable laws regulations drugs medical devices ineffective pose unreasonable health risk us fda could ban products detain seize adulterated misbranded products order recall repair replacement refund products refuse grant pending applications marketing authorization require certificates foreign governments exports andor require us notify health professionals others products present unreasonable risks substantial harm public health us fda may also assess civil criminal penalties us officers employees impose operating restrictions companywide basis enjoin andor restrain certain conduct resulting violations applicable law us fda may also recommend prosecution us department justice adverse regulatory action depending magnitude may restrict us effectively marketing selling products limit ability obtain future clearances approvals could result substantial modification business practices operations equivalent enforcement mechanisms exist different countries conduct business costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world us attention focused states regulatory agencies congress drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices laws regulations enacted require adherence strict compliance standards prevent fraud abuse healthcare industry increased focus interactions financial relationships healthcare companies health care providers various transparency laws regulations require disclosures payments transfers value made physicians teaching hospitals beginning disclosures certain nonphysician practitioners federal foreign laws governing international business practices require strict compliance antibribery standards certain prohibitions respect payments foreign government official payers become potent force market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care generally us government agencies continue efforts repeal modify invalidate provisions patient protection affordable care act aca passed example federal legislation repealed acas individual mandate tax penalty well tax generous employersponsored healthcare plans center medicare medicaid services cms began permitting states impose work requirements persons covered medicaid expansion plans certain federal subsidies insurers ended certain shortterm insurance plans offering full array aca benefits allowed extend duration changes challenged us courts longterm impact remains uncertain aca also subject judicial challenge november us supreme court heard argument texas v azar challenges constitutionality aca pending resolution litigation aca individual mandate buy health insurance remains effect us government also continues propose implement changes medicare part benefit including size manufacturer discounts coverage gap catastrophic phases benefit number additional bills pending congress healthcare reform proposals state level would affect drug pricing medicare medicaid programs changing federal landscape positive negative impacts us healthcare industry much remaining uncertain various provisions federal law potential modification repeal laws ultimately affect industry addition business practices health care industry come increased scrutiny particularly us government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties company relies global supply chains production distribution processes complex subject increasing regulatory requirements may faced unexpected changes resulting covid pandemic brexit may affect sourcing supply pricing materials used company 's products processes also subject complex lengthy regulatory approvals global regulatory landscape also subject change covid pandemic continues affect us global economies us fda health authorities shifted resources priorities meet many challenges presented pandemic pandemicrelated disruptions could negatively impact processing regulatory submissions slow agency review times necessary approval clearance new drugs devices duration severity covid pandemic unpredictable difficult assessemployees human capital management january december number employees approximately employees fulltime equivalent fte positions employee defined individual working fulltime parttime excluding fixed term employees interns coop employees employee data may include full population recently acquired companies individuals longterm disability excluded contingent workers contractors subcontractors also excluded fte represents total number fulltime equivalent positions reflect total number individual employees work parttime strategy company believes employees critical continued success essential element longterm strategy management responsible ensuring policies processes reflect reinforce company 's desired corporate culture including policies processes related strategy risk management ethics compliance companys human capital management strategy built three fundamental focus areas attracting recruiting best talent developing retaining talent empowering inspiring talent underpinning focus areas ongoing efforts cultivate foster culture built diversity equity inclusion dei innovation health wellbeing safety company 's employees encouraged succeed professionally personally helping company achieve business goals culture employee engagement johnson johnson employees guided credo sets forth company 's responsibilities patients consumers customers healthcare professionals employees communities shareholders employees worldwide guided companys code business conduct sets basic requirements business conduct serves foundation company policies procedures guidelines provide additional guidance expected employee behaviors every market operates company c onducts global surveys offer employees ability provide feedback valuable insight help address potential human resources risks identify opportunities improve global employees across countries participated credo survey offered languagesgrowth development continue lead changing healthcare landscape crucial company continue attract retain top talent company believes employees must equipped right knowledge skills provided opportunities grow develop careers accordingly professional development programs educational resources available employees company 's objective foster learning culture helps shape persons unique career path creating robust pipeline talent deliver companys longterm strategies furtherance objective company deploys global approach ensure development everyone regardless career journey employees manager job categories took advantage career opportunities moving across functions country business segment lines including upward promotion lateral transfer excluding employees research development organizations company 's voluntary turnover rate diversity equity inclusion dei company committed workplace diversity cultivating fostering advancing culture equity inclusion enabling employees perform best fundamental company 's continued success companys dei vision change world company 's dei strategy focuses three pillars reflect strategic priorities identified enable company address challenges opportunities presented evolving understanding diversity accelerate companys efforts advance culture inclusion innovation build diverse workforce future enhance business results reputation company 's dei strategy guided internal external insights global best practices continual employee feedback remind company diversity changes location inclusion everywhere compensation benefits part company 's total rewards philosophy company offers competitive compensation benefits attract retain top talent company committed fairness equitable treatment compensation benefits employees levels company observes legal minimum wage provisions exceeds possible company 's total rewards offerings include array programs support employees ' financial physical mental wellbeing including annual performance incentive opportunities pension retirement savings programs health welfare benefits paid time leave programs flexible work schedules employee assistance programs health wellness safety companys investment employee health wellbeing safety built conviction advancing health humanity starts advancing health employees right awareness focus practices tools company ensures employees around world well temporary contractors visitors company 's sites work safely company continuously expanded health wellbeing programs throughout company across globe incorporating new thinking technologies keep offerings bestinclass help employees achieve personal mind body health goals programs practices company advances covers three core dimensions healthy eating healthy movement healthy mind available information companys main corporate website address wwwjnjcom companys sec filings also available companys website wwwinvestorjnjcomseccfm soon reasonably practicable electronically filed furnished sec sec filings also available secs website wwwsecgov investors public note company also announces information wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom use websites communicate investors public products litigation matters possible information post websites could deemed material information therefore encourage investors others interested company review information posted websites conjunction wwwjnjcom company 's sec filings press releases public conference calls webcasts addition amended restated certificate incorporation bylaws written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance committee science technology sustainability committee board directors companys principles corporate governance code business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available wwwinvestorjnjcomgovcfm company 's website provided without charge shareholder submitting awritten request provided information wwwjnjcom wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom deemed part report incorporated filings company makes sec item risk factors investment companys common stock debt securities involves risks uncertainties company seeks identify manage mitigate risks business uncertainties risks difficult predict many outside company 's control therefore eliminated addition information report companys filings sec investors consider carefully factors set forth investors aware possible predict identify factors following meant complete discussion potential risks uncertainties known unknown risks uncertainties materialize companys business results operations financial condition could adversely affected potentially material way risks related business industry operations companys businesses operate highly competitive product markets competitive pressures could adversely affect companys earnings company faces substantial competition three operating segments geographic markets companys businesses compete companies sizes basis costeffectiveness technological innovations intellectual property rights product performance real perceived product advantages pricing availability rate reimbursement company also competes market participants securing rights acquisitions collaborations licensing agreements third parties competition rights product candidates technologies may result significant investment acquisition costs onerous agreement terms company competitors development effective less costly products andor ability secure patent intellectual property rights successfully market products ahead company could negatively impact sales companys existing products well ability bring new products market despite significant prior investment related product development companys pharmaceutical businesses loss patent exclusivity product often followed substantial reduction sales competitors gain regulatory approval generic competing products enter market similar competition triggered loss exclusivity biological product companys medical device businesses technological innovation product quality reputation customer service especially important competitiveness development companies new improved products processes technologies could threaten make companys products technologies less desirable less economical obsolete companys consumer health businesses face intense competition branded products retailers privatelabel brands company fails sufficiently differentiate market brand name consumer products could adversely affect revenues profitability products interruptions delays manufacturing operations could adversely affect companys business sales reputation companys manufacture products requires timely delivery sufficient amounts complex highquality components materials company 's subsidiaries operate manufacturing facilities well sourcing hundreds suppliers around world company past may future face unanticipated interruptions delays manufacturing internal external supply chain manufacturing disruptions occur many reasons including regulatory action production quality deviations safety issues labor disputes sitespecific incidents fires natural disasters hurricanes severe weather events raw material shortages political unrest terrorist attacks epidemics pandemics delays difficulties manufacturing result product shortages declines sales reputational impact well significant remediation related costs associated addressing shortage company relies third parties manufacture certain products failure loss thirdparty manufacturer could result delays increased costs may adversely affect business company relies third parties manufacture certain products depend third party manufacturers allocate us portion manufacturing capacity sufficient meet needs produce products acceptable quality acceptable manufacturing yields deliver products us timely basis acceptable prices however guarantee thirdparty manufacturers able meet nearterm longterm manufacturing requirements could result lost sales adverse effect business risks associated reliance third parties including companys strategic partnership jabil medical devices segment manufacture products include reliance third party regulatory compliance qualityassurance misappropriation companys intellectual property limited ability manage inventory possible breach manufacturing agreement third party possible termination nonrenewal manufacturing agreement third party time costly inconvenient us moreover third party manufacturers suffer damage facilities lose benefits material agreements experience power outages encounter financial difficulties unable secure necessary raw materials suppliers suffer reduction efficiency company may experience significant business disruption event disruption company would need seek source qualified thirdparty manufacturers likely resulting delays increased costs could affect business adversely counterfeit versions products could harm patients negative impact revenues earnings reputation business industry continues challenged vulnerability distribution channels illegal counterfeiting presence counterfeit products growing number markets internet third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards distributors patients counterfeit products may visually indistinguishable authentic version counterfeit medicines pose risk patient health safety conditions manufactured often unregulated unlicensed uninspected unsanitary sites well lack regulation contents industry 's failure mitigate threat counterfeit medicines could adversely impact business reputation impacting patient confidence authentic products potentially resulting lost sales product recalls increased threat litigation addition diversion products authorized market channels may result reduced revenues negatively affect profitability covid pandemic adversely impacted certain aspects companys business could cause disruptions future impact companys business results operations financial condition subject risks associated global health crises pandemics including global outbreak novel coronavirus mutations covid covid pandemic adversely impacted expected continue adversely impact certain aspects companys business results operations financial condition including lower sales reduced customer demand usage certain products spread covid caused company modify business practices including instituting remote work many company 's employees company may take actions may required government authorities company determines best interests patients customers employees business partners company continues monitor situation robust business continuity plans place across global supply chain network help mitigate impact covid efforts may completely prevent business adversely affected future impacts remain uncertain us countries begun begin reopen economies extent covid impact company 's future operations depend many factors predicted confidence including duration outbreak resurgence covid infections could result imposition new mandates prolonged restrictive measures implemented order control spread disease continued global spread covid could adversely impact company 's operations including among things manufacturing operations supply chain including thirdparty suppliers sales marketing clinical trial operations factors could adversely affect company 's business financial results global economic conditions generally also face uncertainties related efforts develop covid vaccine candidate including uncertainties related risk development programs may successful commercially viable receive approval emergency use authorization regulatory authorities risks associated clinical trial data including analyses existing preclinical clinical trial data may inconsistent data used selection jnj vaccine candidate dose level phase ensemble trial risk clinical trial data subject differing interpretations assessments including peer reviewpublication process scientific community generally regulatory authorities disruptions relationships us thirdparty suppliers external manufacturers risk companies may produce superior competitive products risk demand products may develop may longer exist risks related availability raw materials manufacture products risk may able recoup costs associated rd manufacturing efforts risks associated changes way approach provide additional research funding potential drug development related covid risk may able create scale manufacturing capacity timely basis may experience manufacturing delays manufacturing site activated access logistics supply channels commensurate global demand potential approved vaccine product candidate would negatively impact ability supply estimated numbers doses vaccine candidate within projected time periods indicated challenges risks associated pace vaccine development program pricing access challenges products including usin addition extent covid pandemic adversely affects business financial results may also effect heightening many risks described risk factors section incorporated reference herein ncluding risks relating companys effective tax rate result changes consumption well changes laws relating supply companys products given developments concerning covid pandemic constantly evolving additional impacts risks may arise including litigation presently known company risk related government regulation legal proceedings global sales companys pharmaceutical medical devices segments may negatively impacted healthcare reforms increasing pricing pressures sales companys pharmaceutical medical device products significantly affected reimbursements thirdparty payers government healthcare programs private insurance plans managed care organizations part various efforts contain healthcare costs payers putting downward pressure prices products reimbursed us increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries part due continued consolidation among health care providers could result pricing pressures addition increased political scrutiny could result additional pricing pressures outside us numerous major markets including eu united kingdom japan pervasive government involvement funding healthcare regard directly indirectly impose price controls limit access reimbursement companys products reduce value intellectual property protection company subject significant legal proceedings result significant expenses fines reputational damage ordinary course business johnson johnson subsidiaries subject numerous claims lawsuits involving various issues patent disputes product liability claims product sales marketing pricing practices violate various antitrust unfair trade practices andor consumer protection laws company 's significant legal proceedings described note legal proceedings notes consolidated financial statements included item report litigation general securities derivative action class action multidistrict litigation particular expensive disruptive matters may include thousands plaintiffs may involve parties seeking large andor indeterminate amounts including punitive exemplary damages may remain unresolved several years example company defendant numerous lawsuits arising use body powders containing talc primarily johnsons baby powder companys sale manufacturing marketing opioids company believes substantial defenses matters feasible predict ultimate outcome litigation company could future required pay significant amounts result settlements judgments matters potentially excess accruals including matters company could held jointly severally liable among defendants resolution increase accruals one matters reporting period could material adverse effect company 's results operations cash flows period company purchase thirdparty product liability insurance however company utilizes whollyowned captive insurance company subject certain limits product reliability safety effectiveness concerns significant negative impacts sales results operations lead litigation cause reputational damage concerns product safety whether raised internally litigants regulators consumer advocates whether based scientific evidence result safety alerts product recalls governmental investigations regulatory action part us food drug administration counterpart countries private claims lawsuits payment fines settlements declining sales reputational damage circumstances also result damage brand image brand equity consumer trust companys products product recalls past could future prompt government investigations inspections shutdown manufacturing facilities continued product shortages related sales declines significant remediation costs reputational damage possible civil penalties criminal prosecution company faces significant regulatory scrutiny imposes significant compliance costs exposes company government investigations legal actions penalties like companies healthcare industry company subject extensive regulation investigations legal action national state local government agencies us countries operate regulatory issues regarding compliance current good manufacturing practices cgmp comparable quality regulations foreign countries manufacturers drugs devices consumer products lead fines penalties product recalls product shortages interruptions production delays new product approvals litigation addition marketing pricing sale companys products subject regulation investigations legal actions including federal food drug cosmetic act medicaid rebate program federal state false claims acts state unfair trade practices acts consumer protection laws scrutiny health care industry business practices government agencies state attorneysgeneral us resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment participation government healthcare programs debarment could material adverse effect companys business results operations significant current investigations litigation brought government agencies described note legal proceedingsgovernment proceedings notes consolidated financial statements included item report changes tax laws exposures additional tax liabilities could negatively impact companys operating results changes tax laws regulations around world could negatively impact companys effective tax rate results operations change statutory tax rate country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes statutory tax rate may occur time related expense benefit recorded may material fiscal quarter year law change enacted see note income taxes additional information company conducts business files tax returns numerous countries addressing tax audits disputes many tax authorities connection organization economic cooperation development base erosion profit shifting beps project companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries company regularly assesses likely outcomes tax audits disputes determine appropriateness tax reserves however tax authority could take position tax treatment contrary companys expectations could result tax liabilities excess reserves risks related intellectual property company may able successfully secure defend intellectual property rights essential companys businesses company owns licenses significant number patents proprietary rights relating products manufacturing processes rights essential companys businesses materially important companys results operations public policy within outside us become increasingly unfavorable toward intellectual property rights company certain obtain adequate patent protection new products technologies united states important markets protections granted last long originally anticipated competitors routinely challenge validity extent companys owned licensed patents proprietary rights litigation interferences oppositions proceedings inter partes review ipr proceedings united states patent trademark office uspto proceedings absorb resources protracted well unpredictable addition challenges companys products infringe patents third parties could result need pay past damages future royalties adversely affect competitive position sales products question company faced increasing patent challenges third parties seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products us manufacturers generic versions innovative human pharmaceutical products may challenge validity claim noninfringement innovator products abbreviated new drug application anda process fda related anda litigation biologics price competition innovation act bpcia enacted created new regulatory pathway approval fda biosimilar alternatives innovatordeveloped biological products also created mechanisms biosimilar applicants challenge patents innovator biologics ipr process uspto also used competitors challenge patents asserted litigation event company successful defending patents challenges upon atrisk launch despite pending patent infringement litigation generic biosimilar firm product company lose major portion revenues referenced product short period time current legal proceedings involving companys patents intellectual property rights described note legal proceedingsintellectual property notes consolidated financial statements included item report risks related product development regulatory approval commercializationsignificant challenges delays companys innovation development new products technologies indications could adverse impact companys longterm success companys continued growth success depends ability innovate develop new differentiated products services address evolving health care needs patients providers consumers development successful products technologies also necessary offset revenue losses companys existing products lose market share due various factors competition loss patent exclusivity new products introduced within past five years accounted approximately sales company certain whether able develop license otherwise acquire companies products technologies whether particular product candidates granted regulatory approval approved whether products commercially successful company pursues product development internal research development well collaborations acquisitions joint ventures licensing arrangements third parties contexts developing new products particularly pharmaceutical biotechnology products medical devices requires significant investment resources many years biopharmaceutical research development programs result commercially viable products process depends many factors including ability discern patients health care providers future needs develop promising new compounds strategies technologies achieve successful clinical trial results secure effective intellectual property protection obtain regulatory approvals timely basis reach market successfully differentiate companys products competing products approaches treatment new products enhancements existing products may accepted quickly significantly marketplace due product price competition changes customer preferences healthcare purchasing patterns resistance healthcare providers uncertainty thirdparty reimbursement even following initial regulatory approval success product adversely impacted safety efficacy findings larger realworld patient populations well market entry competitive products risk related financial economic market conditions company faces variety risks associated conducting business internationally companys extensive operations business activity outside us accompanied certain financial economic political risks including listed foreign currency exchange fiscal approximately companys sales occurred outside us approximately europe western hemisphere excluding us asiapacific africa region changes nonus currencies relative us dollar impact companys revenues expenses company uses financial instruments mitigate impact fluctuations currency exchange rates cash flows unhedged exposures continue subject currency fluctuations addition weakening strengthening us dollar may result significant favorable unfavorable translation effects operating results companys nonus business activity translated us dollars inflation currency devaluation risks company faces challenges maintaining profitability operations economies experiencing high inflation rates company accounted operations argentina beginning fiscal third quarter venezuela highly inflationary prior threeyear cumulative inflation rate surpassed company strives maintain profit margins areas cost reduction programs productivity improvements periodic price increases might experience operating losses result continued inflation addition impact currency devaluations countries experiencing high inflation rates significant currency exchange fluctuations could negatively impact companys operating results illegal importation pharmaceutical products illegal importation pharmaceutical products countries government price controls market dynamics result lower prices may adversely affect companys sales profitability us countries company operates exception limited quantities prescription drugs personal use foreign imports pharmaceutical products illegal current us law however volume illegal imports continues rise ability patients customers obtain lowerpriced imports grown significantly antibribery regulations company subject various federal foreign laws govern international business practices respect payments government officials laws include us foreign corrupt practices act fcpa prohibits us publicly traded companies promising offering giving anything value foreignofficials corrupt intent influencing foreign official purpose helping company obtain retain business gain improper advantage companys business heavily regulated therefore involves significant interaction foreign officials also many countries outside us health care providers prescribe human pharmaceuticals employed government purchasers human pharmaceuticals government entities therefore companys interactions prescribers purchasers subject regulation fcpa addition us application enforcement fcpa various jurisdictions company operates laws regulations including uk bribery act aimed preventing penalizing corrupt anticompetitive behavior enforcement activities laws could subject company additional administrative legal proceedings actions could include claims civil penalties criminal sanctions administrative remedies including exclusion health care programs legal social political risks risks inherent conducting business globally include protective economic policies taken governments trade protection measures importexport licensing requirements compliance local regulations laws including countries regulatory requirements restricting companys ability manufacture sell products relevant market diminished protection intellectual property contractual rights certain jurisdictions potential nationalization expropriation companys foreign assets political social upheavals economic instability repression human rights issues geopolitical events including natural disasters disruptions markets due war armed conflict terrorism epidemics pandemics failure maintain satisfactory credit rating could adversely affect liquidity capital position borrowing costs access capital markets currently maintain investment grade credit ratings moody 's investors service standard poor 's ratings services rating agencies routinely evaluate us ratings longterm shortterm debt based number factors downgrade credit ratings credit rating agency whether result actions factors beyond control increase cost borrowing indebtedness may incur reduce market capacity commercial paper require posting additional collateral derivative contracts assurance able maintain credit ratings additional actual anticipated changes downgrades credit ratings including announcement ratings review downgrade may negative impact liquidity capital position access capital markets risks business depends ability recruit retain talented highly skilled employees diverse workforce continued growth requires us recruit retain talented employees representing diverse backgrounds experiences skill sets market highly skilled workers leaders industry extremely competitive ability compete depends ability hire develop motivate highly skilled personnel areas organization maintaining brand reputation well diverse equitable inclusive work environment enables us attract top talent less successful recruiting efforts retain highly skilled workers key leaders ability develop deliver successful products services may adversely affected addition effective succession planning important longterm success unsuccessful implementation succession plans failure ensure effective transfer knowledge smooth transitions involving key employees could adversely affect business financial condition results operations information security incident including cybersecurity breach could negative impact companys business reputation meet business objectives company relies internal technology systems networks third parties vendors process store sensitive data including confidential research business plans financial information intellectual property personal data may subject legal protection ensure continuity companys supply chain extensive information security cybersecurity threats affect companies globally pose risk security availability systems networks confidentiality integrity availability companys sensitive data company continually assesses threats makes investments increase internal protection detection response capabilities well ensure companys thirdparty providers required capabilities controls address risk date company experienced material impact business operations resulting information cybersecurity attacks however frequently changing attack techniques along withthe increased volume sophistication attacks potential company adversely impacted impact could result reputational competitive operational business harm well financial costs regulatory action company maintains cybersecurity insurance event information security cyber incident however coverage may sufficient cover financial legal business reputational losses climate change legal regulatory market measures address climate change may negatively affect business results operations climate change resulting increased concentrations carbon dioxide greenhouse gases atmosphere could present risks operations including adverse impact global temperatures weather patterns frequency severity extreme weather natural disasters natural disasters extreme weather conditions hurricane tornado earthquake wildfire flooding may pose physical risks facilities disrupt operation supply chain impacts changing climate water resources may result water scarcity limiting ability access sufficient highquality water certain locations may increase operational costs concern climate change may also result new additional legal regulatory requirements designed reduce greenhouse gas emissions andor mitigate effects climate change environment laws regulations stringent current legal regulatory obligations may experience disruption increase costs associated sourcing manufacturing distribution products may adversely affect business results operations financial condition item b unresolved staff comments applicable item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands consumer health pharmaceutical medical devices worldwide total within us five facilities used consumer health segment five pharmaceutical segment medical devices segment outside us facilities used consumer health segment pharmaceutical segment medical devices segment locations manufacturing facilities major geographic areas world follows number square feet geographic area facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed company maintains numerous office warehouse facilities throughout world research facilities also discussed item managements discussion analysis results operations financial condition report company 's subsidiaries generally seek rather lease manufacturing facilities although principally nonus locations leased office warehouse facilities often leased company also engages contract manufacturers company committed maintaining properties good operating condition mcneilppc inc johnson johnson consumer inc mcneilppc continues operate consent decree signed fda governs certain mcneil consumer healthcare manufacturing operations requires mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree following fda inspections mcneilppc received notifications fda three manufacturing facilities conformity applicable laws regulations commercial production restarted consent decree receiving notice fda compliance applicable laws regulations three facilities subject fiveyear audit period thirdparty cgmp expert thirdparty expert continued reassess sites various times mcneilppc awaiting fda inspections facilities delayed due covid segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements included item report item legal proceedings information called item incorporated herein reference information set forth note legal proceedings notes consolidated financial statements included item report addition johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation item mine safety disclosures applicable executive officers registrant listed executive officers company family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including information alex gorsky also executive officer incorporated herein reference material captioned item election directors proxy statement name age position joaquin duato vice chairman executive committee peter fasolo phd member executive committee executive vice president chief human resources officer b alex gorsky chairman board directors chairman executive committee chief executive officer ashley mcevoy member executive committee executive vice president worldwide chairman medical devices c thibaut mongon member executive committee executive vice president worldwide chairman consumer health michael e sneed member executive committee executive vice president global corporate affairs chief communication officer e paulus stoffels md vice chairman executive committee chief scientific officer f jennifer l taubert member executive committee executive vice president worldwide chairman pharmaceuticals g michael h ullmann member executive committee executive vice president general counsel h kathryn e wengel member executive committee executive vice president chief global supply chain officer joseph j wolk member executive committee executive vice president chief financial officer j mr j duato joined company janssenfarmaceutica sa spain subsidiary company held executive positions increasing responsibility pharmaceutical sector named company group chairman pharmaceuticals named worldwide chairman pharmaceuticals mr duato became member executive committee named executive vice president worldwide chairman pharmaceuticals july mr duato promoted vice chairman executive committee responsibility company 's pharmaceutical consumer health sectors supply chain information technology global services health wellness groups b dr p fasolo joined company vice president worldwide human resources cordis corporation subsidiary company subsequently named vice president global talent management company left johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo returned company vice president global human resources became member executive committee april named executive vice president chief human resources officer dr fasolo responsibility global talent recruiting diversity compensation benefits employee relations aspects human resources agenda company c ms mcevoy joined company assistant brand manager mcneil consumer health subsidiary company advancing positions increasing responsibilities appointed company group chairman vision care followed company group chairman consumer medical devices july ms mcevoy promoted executive vice president worldwide chairman medical devices became member executive committee ms mcevoy responsibility surgery orthopaedics interventional solutions eye health businesses across ethicon depuy synthes biosense webster johnson johnson vision mr mongon joined company director marketing vision care group france subsequently held general management positions country manager france belgium north africa managing director latin america president asiapacific mr mongon transitioned pharmaceutical sector global commercial strategy leader neuroscience therapeutic area joining consumer health sector company group chairman asiapacific promoted executive vice president worldwide chairman consumer health became member executive committee mr mongon responsibility global development johnson johnsons health wellness products solutions beauty otc oral care baby care womens health wound care e mr e sneed joined company marketing assistant personal products company subsidiary company gained increased responsibilities executive positions across global enterprise mr sneed appointed company group chairman consumer north america followed company group chairman vision care franchise became vice president global corporate affairs chief communications officer mr sneed appointed executive vice president global corporate affairs chief communications officer january became member executive committee july leading company 's global marketing communication design philanthropy functions f dr p stoffels rejoined company acquisition tibotec virco nv chief executive officer virco nv chairman tibotec nv appointed company group chairman global virology assumed role company group chairman pharmaceuticals dr stoffels appointed global head research development pharmaceuticals became worldwide chairman pharmaceuticals dr stoffels appointed chief scientific officer became member executive committee dr stoffels named executive vice president chief scientific officer dr stoffels promoted vice chairman executive committee chief scientific officer responsible companys innovation agenda across pharmaceutical medical devices consumer health sectors product safety strategy companys global public health strategy g ms j l taubert joined company worldwide vice president johnson johnson pharmaceutical services subsidiary company held several executive positions increasing responsibility pharmaceutical sector appointed company group chairman north america pharmaceuticals became company group chairman americas pharmaceuticals july ms taubert promoted executive vice president worldwide chairman pharmaceuticals became member executive committee ms taubert responsibility immunology infectious diseases neuroscience oncology cardiovascular metabolism pulmonary hypertension businesses throughout janssen h mr h ullmann joined company corporate attorney law department appointed corporate secretary served role time also held various management positions law department named general counsel medical devices diagnostics appointed vice president general counsel became member executive committee april mr ullmann named executive vice president general counsel mr ullmann worldwide responsibility legal government affairs policy global security aviation health care compliance global brand protection privacy ms k e wengel joined company project engineer engineering supervisor janssen subsidiary company tenure company held variety strategic leadership executive positions across global enterprise roles within operations quality engineering new productsinformation technology technical business functions ms wengel became first chief quality officer company promoted vice president johnson johnson supply chain july promoted executive vice president chief global supply chain officer became member executive committee j mr j j wolk joined company finance manager business development orthomcneil subsidiary company years held variety senior leadership roles several segments functions across company 's subsidiaries pharmaceuticals medical devices supply chain served vice president finance chief financial officer janssen pharmaceutical companies johnson johnson mr wolk became vice president investor relations july appointed executive vice president chief financial officer became member executive committee mr wolk plays strategic role overall management company leads development execution company 's global longterm financial strategy part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference following sections report note common stock stock option plans stock compensation agreements notes consolidated financial statements included item item security ownership certain beneficial owners management related stockholder matters equity compensation plan information issuer purchases equity securities following table provides information respect common stock purchases company fiscal fourth quarter common stock purchases open market made part systematic plan meet needs companys compensation programs repurchases also include stockforstock option exercises settled fiscal fourth quarter total number maximum number shares units approximate dollar purchased part value shares total number publicly units may yet shares avg price announced plans purchased fiscal period purchased paid per share programs plans programs september october october november november january total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock openmarket transactions purchased openmarket transactions part systematic plan meet needs companys compensation programs item reserved item managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer health previously referred consumer pharmaceutical medical devices consumer health segment includes broad range products used baby care oral care skin healthbeauty overthecounter pharmaceutical womens health wound care markets products marketed general public sold online ecommerce retail outlets distributors throughout world pharmaceutical segment focused six therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery interventional solutions cardiovascular neurovascular eye health fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer health pharmaceutical medical devices business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property company 's product portfolio important companys success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion managements objectives credo foundation companys purpose blend heart science ingenuity profoundly change trajectory health humanity company committed bringing full breadth depth ensure health people today future generations united around common ambition company poised fulfill purpose successfully meet demands rapidly evolving markets competes company broadly based human healthcare committed creating value developing accessible high quality innovative products services new products introduced within past five years accounted approximately sales billion invested research development billion spent acquisitions reflecting managements commitment create lifeenhancing innovations create value partnerships profoundly change trajectory health humanity critical driver companys success diverse employees worldwide employees empowered inspired lead companys credo purpose guides allows every employee use companys reach size advance company 's purpose also lead agility urgency leveraging extensive resources across enterprise enables company innovate execute excellence ensures company remain focused addressing unmet needs society every day invest enduring impact ultimately delivering value patients consumers healthcare professionals employees communities shareholdersresults operations analysis consolidated sales discussion results operations financial condition pertaining fiscal years see companys annual report fiscal year ended december item management 's discussion analysis results operations financial condition worldwide sales increased billion compared increase sales changes consisted following sales increasedecrease due volume price currency total net impact acquisitions divestitures worldwide sales growth negative impact negative impact sales us companies billion billion represents increases sales international companies billion billion represents decrease increase fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales companies europe achieved growth compared prior year included operational growth positive currency impact sales companies western hemisphere excluding us experienced sales decline compared prior year included operational growth offset negative currency impact sales companies asiapacific africa region experienced sales decline compared prior year including operational decline partially offset positive currency impact results benefited inclusion rd week see note consolidated financial statements annual closing date details company estimated fiscal year sales growth rate enhanced approximately additional week added days sales also added full week 's worth operating costs therefore net earnings impact negligible company utilized three wholesalers distributing products three segments represented approximately total consolidated revenues company three wholesalers distributing products three segments represented approximately total consolidated revenuesnote values may rounded analysis sales business segments consumer health segment consumer health segment sales billion increase included operational growth negative currency impact us consumer health segment sales billion increase international sales billion decrease included operational decline negative currency impact acquisitions divestitures net negative impact operational sales growth worldwide consumer health segment major consumer health franchise sales change vs dollars millions otc skin healthbeauty oral care baby care womens health wound careother total consumer health sales previously referred consumer previously referred beauty otc franchise sales billion increased compared prior year growth primarily attributable sales tylenol driven covid stocking demand zyrtec due competitor product stock pepcid due competitive product withdrawal us increased consumption antismoking aids international sales negatively impacted covid low incidence cough flu skin healthbeauty franchise sales billion decrease compared prior year decline primarily due negative covid related impacts sku rationalization partially offset growth ecommerce new product innovation oral care franchise sales billion increased compared prior year primarily attributable sales listerine mouthwash due us ecommerce club channel growth increased stocking demand related covid new product launches asia pacific baby care franchise sales billion decrease compared prior year decline primarily due covid related impacts sku rationalization baby center divestiture us partially offset strength aveeno baby womens health franchise sales billion decrease compared prior year decline primarily driven covid impacts wound careother franchise sales billion increase compared prior year growth due strong performance neosporin bandaid brand adhesive bandages covid related demand asia pacific region pharmaceutical segment pharmaceutical segment sales billion increase included operational growth negative currency impact us sales billion increase international sales billion increase included operational growth negative currency impact acquisitions divestitures net negative impact operational sales growth worldwide pharmaceutical segment adjustments previous reserve estimates positively impacted pharmaceutical segment operational growth approximately fiscal years major pharmaceutical therapeutic area sales change vs dollars millions total immunology remicade simponi simponi aria stelara tremfya immunology total infectious diseases edurant rilpivirine prezista prezcobix rezolsta symtuza infectious diseases total neuroscience concerta methylphenidate invega sustenna xeplion invega trinza trevicta risperdal consta neuroscience total oncology darzalex erleada imbruvica velcade zytiga abiraterone acetate oncology total pulmonary hypertension opsumit uptravi pulmonary hypertension total cardiovascular metabolism xarelto invokana invokamet procrit eprex total pharmaceutical sales certain prior year amounts reclassified conform current year presentation percentage greater meaningful previously included oncology inclusive tracleer previously disclosed separately immunology products sales billion representing increase compared prior year driven strong uptake stelara ustekinumab crohn 's disease ulcerative colitis strength tremfya guselkumab psoriasis partially offset covid related demand lower sales remicade infliximab due increased discountsrebates biosimilar competition patents remicade infliximab certain countries europe expired february biosimilar versions remicade introduced certain markets outside united states resulting reduction sales remicade markets additional biosimilar competition likely result reduction sales remicade markets outside united states united states biosimilar version remicade introduced additional competitors continue enter market continued infliximab biosimilar competition us market result reduction us sales remicade infectious disease products sales billion representing increase compared prior year primarily due strong sales symtuza juluca partially offset lower sales prezista prezcobix rezolsta due increased competition loss exclusivity prezista certain countries outside us neuroscience products sales billion representing increase compared prior year paliperidone longacting injectables growth driven sales invega sustenna xeplion paliperidone palmitate invega trinza trevicta new patient starts persistence growth partially offset migration risperdal consta risperidone declines concerta methylphenidate due competitive entrants oncology products achieved sales billion representing increase compared prior year contributors growth strong sales darzalex daratumumab driven patient uptake lines therapy launch subcutaneous formulation us eu imbruvica ibrutinib due market growth globally maintaining strong share continued global launch uptake share gains erleada apalutamide additionally growth negatively impacted declining sales zytiga abiraterone acetate velcade bortezomib due generic competition pulmonary hypertension products achieved sales billion representing increase compared prior year sales growth opsumit macitentan uptravi selexipag due continued share gains market growth additionally sales tracleer bosentan negatively impacted generics migration opsumit cardiovascularmetabolismother products sales billion decline compared prior year sales growth invokana invokamet canagliflozin due market growth favorable channel mix dynamics us strength european region partially offset us share declines due competitive pressures growth xarelto rivaroxaban due demand growth partially offset higher rebates lower sales procrit eprex epoetin alfa due biosimilar competition company advanced pipeline several regulatory submissions approvals new drugs additional indications existing drugs follows product name us eu us eu chemical name indication approval approval filing filing amivantamab treatment patients metastatic nonsmall cell lung cancer egfr exon insertion mutations darzalex combination regimen newly diagnosed transplant daratumumab eligible patients multiple myeloma darzalex combination carfilzomib dexamethasone daratumumab patients relapsedrefractory multiple myeloma darzalex faspro subcutaneous formulation daratumumab daratumumab treatment patients multiple myeloma hyaluronidase erleada treatment metastatic castrationsensitive prostate apalutamide cancer imbruvica combination rituximab treatment chronic ibrutinib lymphocytic leukemia invokana treatment diabetic kidney disease canagliflozin rilpivirine monthly injectable two drug regimen treatment cabotegravir hiv paliperidone pamitate treatment schizophrenia month ponesimod treatment adults relapsed multiple sclerosis simponi aria treatment polyarticular juvenile idiopathic arthritis golimumab juvenile psoriatic arthritis sirturo bedaquilinecombination therapy treat children pulmonary multidrugresistant tuberculosis spravato rapid reduction depressive symptoms adults esketamine major depressive disorder active suicidal ideation intent stelara treatment pediatric patients moderate severe ustekinumab plaque psoriasis tremfya treatment adults active psoriatic arthritis guselkumab uptravi iv pulmonary arterial hypertension xarelto new indication expand use patients peripheral rivaroxaban artery disease zabdeno preventive ebola vaccine adzebov mvabea mvabnfilo medical devices segment medical devices segment sales billion decrease included operational decrease negative currency impact us sales billion decrease compared prior year international sales billion decrease compared prior year operational decrease negative currency impact net impact acquisitions divestitures medical devices segment worldwide operational sales growth negative divestiture advanced sterilization products asp impact approximately growth negatively impacted covid associated deferral medical procedures major medical devices franchise sales change vs dollars millions surgery advanced general orthopaedics hips knees trauma spine sports vision contact lensesother surgical interventional solutions total medical devices sales certain prior year amounts reclassified conform current year presentation includes specialty surgery previously disclosed separately previously referred spine surgery franchise sales billion decrease decline advanced surgery primarily driven negative impact covid competitive pressures us partially offset success new products outside us recovery isolated supply disruption prior year related surgiflo decline general surgery primarily driven negative impact covid asp divestiture orthopaedics franchise sales billion decrease decline hips driven negative impact covid partially offset leadership position anterior approach strong market demand actis stem enabling technologies kincise velys hip navigation decline knees driven negative impact covid decline trauma driven negative impact covid partially offset strength new products decline spine sports driven negative impact covid partially offset uptake new products vision franchise sales billion decrease contact lensesother operational decline due negative impact covid surgical operational decline primarily driven negative impact covid competitive pressures us interventional solutions franchise achieved sales billion increase growth electrophysiology business driven atrial fibrillation procedure growth coupled strength new products market recovery offsetting negative impacts covid analysis consolidated earnings provision taxes income consolidated earnings provision taxes income billion billion years respectively percent sales consolidated earnings provision taxes income respectively dollars billions percentages chart percent total sales cost products sold selling marketing administrative expenses dollars billions percentages chart percent total sales cost products sold increased percent sales driven medical device idle capacity costs associated covid related production slow downs establishment obsolescence reserves fixed cost deleveraging associated impact covid medical devices business supply chain costs associated development covid vaccine pharmaceutical business partially offset favorable mix within pharmaceutical business favorable product mix higher percentage sales coming pharmaceutical business intangible asset amortization expense included cost products sold billion billion years respectivelyselling marketing administrative expenses decreased percent sales driven leveraging pharmaceutical consumer health businesses portfolio investment optimization including execution ongoing sku rationalization program consumer health business favorable segment mix higher percentage sales coming pharmaceutical business partially offset negative impact sales resulting covid medical devices business research development expense research development expense segment business follows dollars millions amount sales amount sales consumer health pharmaceutical medical devices total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products upfront payments developmental milestones improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products research development increased percent sales primarily driven segment mix driven higher percentage sales generated pharmaceutical business versus prior year negative covid impact medical devices sales increased investment medical devices business related robotics digital programs portfolio progression including covid vaccine pharmaceutical business net governmental reimbursements research facilities located us belgium brazil china france germany india israel netherlands poland singapore sweden switzerland united kingdom additional rd support countries inprocess research development iprd fiscal year company recorded iprd charge billion primarily related partial impairment due timing progression one digital surgery platforms acquired auris health acquisition fiscal year company recorded iprd charge billion remaining intangible asset value related development program al investigational drug treatment respiratory syncytial virus rsv human metapneumovirus hmpv acquired acquisition alios biopharma inc impairment charge based additional information including clinical data became available led company 's decision abandon development al income expense net income expense net account company records gains losses related sale writedown certain investments equity securities held johnson johnson innovation jjdc inc jjdc unrealized gains losses investments gains losses divestitures certain transactional currency gains losses acquisitionrelated costs litigation accruals settlements well royalty income income expense net fiscal year unfavorable billion compared prior year primarily due followingdollars billionsincomeexpense change litigation expense acquisition integration related unrealized gainslosses securities equity stepup gain related dr cilabo divestiture gains restructuring related total income expense net litigation expense primarily associated talc related reserves certain settlements billion litigation expense primarily related agreement principle settle opioid litigation billion primarily driven contingent consideration reversal approximately billion related timing certain developmental milestones associated auris health acquisition included divestiture asp interest income expense fiscal year included net interest expense million compared income million fiscal year primarily due reduced interest income resulting lower rates interest earned cash balances higher average debt balance partially offset lower average debt interest rate higher average cash balance cash cash equivalents marketable securities totaled billion end averaged billion compared cash cash equivalents marketable securities total billion billion average cash balance total debt balance end billion average debt balance billion compared billion end average debt balance billion fiscal third quarter company issued approximately billion commercial paper approximately billion outstanding year end fiscal third quarter company issued senior unsecured notes total billion income tax segment income loss tax segment business follows income tax segment sales percent segment sales dollars millions consumer health pharmaceutical medical devices total less net expense allocated segments earnings provision taxes income see note consolidated financial statements details amounts allocated segments include interest income expense general corporate income expense consumer health segment consumer health segment loss tax percent sales versus income tax decrease income tax percent sales primarily driven following higher litigation expense billion vs billion primarily associated talc related reserves certain settlements fiscal year included gain billion related company 's previously held equity investment dr cilabo partially offset portfolio investment optimization including execution ongoing sku rationalization program pharmaceutical segment pharmaceutical segment income tax percent sales versus increase income tax percent sales primarily driven following lower litigation expense billion vs billion primarily related agreement principle settle opioid litigation billion billion inprocess research development charge billion fiscal related alios lower acquisition integration related costs fiscal leveraging selling marketing administrative expense medical devices segment medical devices segment income tax percent sales versus decrease income tax percent sales primarily driven following gain billion related asp divestiture recorded fiscal idle capacity costs associated covid related production slow downs fiscal establishment obsolescence reserves fixed cost deleveraging associated impact covid fiscal negative impact covid sales fiscal inprocess research development charge billion fiscal primarily related auris health acquisition partially offset contingent consideration reversal approximately billion fiscal related timing certain developmental milestones associated auris health acquisition litigation expense billion vs billion restructuring fiscal second quarter company announced plans implement actions across global supply chain intended enable company focus resources increase investments critical capabilities technologies solutions necessary manufacture supply product portfolio future enhance agility drive growth company expects supply chain actions include expanding use strategic collaborations bolstering initiatives reduce complexity improving costcompetitiveness enhancing capabilities optimizing network discussions regarding specific future actions ongoing subject relevant consultation requirements finalized total company expects actions generate approximately billion annual pretax cost savings substantially delivered company expects record pretax restructuring charges approximately billion company estimates approximately cumulative pretax costs result cash outlays company recorded pretax charge billion included following lines consolidated statement earnings billion restructuring billion income expense billion cost products sold total project costs approximately billion recorded since restructuring announced see note consolidated financial statements additional details related restructuring programs provision taxes income worldwide effective income tax rate fiscal first quarter internal revenue service published final regulations addressing requirements tax deductibility settlement payments company recorded pretax reserve billion fiscal year based agreement principle settle opioid litigation recorded additional pretax billion fiscal third quarter upon effective rate applied discussion related fiscal provision taxes refer note consolidated financial statements liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary sources uses cash contributed billion decrease dollars billions q cash cash equivalents balance cash generated operating activities net cash used investing activities net cash used financing activities effect exchange rate rounding q cash cash equivalents balance addition company billion marketable securities end fiscal year billion end fiscal year see note consolidated financial statements additional details cash cash equivalents marketable securitiescash flow operations billion result dollars billions net earnings noncash expenses adjustments primarily depreciation amortization stockbased compensation asset writedowns credit losses accounts receivable allowances partially offset deferred tax provision net gain sale assetsbusinesses decrease accounts receivable increase accounts payable accrued liabilities current noncurrent liabilities increase inventories current noncurrent assets contingent consideration reversal related timing certain developmental milestones associated auris health acquisition rounding cash flow operations investing activities use billion cash primarily used dollars billions primarily related acquisitions momenta bermekimab related assets xbiotech inc well acquisition outstanding shares verb surgical inc additions property plant equipment net purchases investments credit support agreements activity net proceeds disposal assetsbusinesses net primarily licenses milestones net cash used investing activities financing activities use billion cash primarily used dollars billions dividends shareholders repurchase common stock net proceeds short long term debt proceeds stock options exercisedemployee withholding tax stock awards net credit support agreements activity net net cash used financing activities january company 's notes payable longterm debt excess cash cash equivalents marketable securities january net debt position billion compared prior year billion increase net debt position due increased borrowings fiscal third quarter debt balance end billion compared billion considering recent market conditions ongoing covid crisis company evaluated operating cash flows liquidity profile foresee significant incremental risk company anticipates operating cash flows ability raise funds external sources borrowing capacity existing committed credit facilities access commercial paper markets continue provide sufficient resources fund operating needs including talc litigation agreement principle settle opioid litigation majority may paid next two three years addition company monitors global capital markets ongoing basis time time may raise capital market conditions favorable fiscalthird quarter company issued approximately billion commercial paper approximately billion outstanding year end fiscal third quarter company issued senior unsecured notes total billion additional details borrowings see note consolidated financial statements net proceeds offering used fund momenta pharmaceuticals inc acquisition closed october general corporate purposes additionally result tax cuts jobs act tcja company access cash outside us significantly reduced cost following table summarizes companys material contractual obligations aggregate maturities january satisfy obligations company intends use cash operations tax legislation interest dollars millions tcja debt obligations debt obligations total total tax matters see note consolidated financial statements table include activity related business combinations companys approximate billion contractual supply commitments associated development covid vaccine financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar january market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar january market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least investment grade credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote company entered credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements see note consolidated financial statements additional details credit support agreements company invests fixed rate floating rate interest earning securities carry degree interest rate risk fair market value fixed rate securities may adversely impacted due rise interest rates floating rate securities may produce less income predicted interest rates fall basis points change spread companys interest rate sensitive investments would either increase decrease unrealized value cash equivalents current marketable securities approximately million company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either bids provided bankslondon interbank offered rates libor secured overnight financing rate sofr swap curve applicable market rate allowed plus applicable margins commitment fees agreement material total borrowings end billion billion respectively increase borrowings issuance notes market conditions favorable net debt cash current marketable securities net debt billion compared net debt billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend summary borrowings found note consolidated financial statements dividends company increased dividend th consecutive year cash dividends paid per share per share january board directors declared regular cash dividend per share payable march shareholders record february information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaap preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock based awards extent covid impacts companys business financial results depend numerous evolving factors including limited magnitude duration covid extent impact worldwide macroeconomic conditions including interest rates employment rates health insurance coverage speed anticipated recovery governmental business reactions pandemic company assessed certain accounting matters generally require consideration forecasted financial information context information reasonably available company unknown future impacts covid january date report accounting matters assessed included limited companys allowance doubtful accounts credit losses inventory related reserves accrued rebates associated reserves carrying value goodwill longlived assets material impact companys consolidated financial statements year ended january companys future assessment magnitude duration covid well factors could result material impacts companys consolidated financial statements future reporting periods revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted variable consideration recorded reduction sales product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer health pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products frominventory returned products sales returns reserve total company approximately annual net trade sales fiscal years promotional programs product listing allowances cooperative advertising arrangements recorded period related sales continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers years presented profitshare payments less total revenues included sales customers addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative selling price upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impact tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended january december consumer health segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million december recorded contra assetpharmaceutical segment balance beginning paymentscredits balance dollars millions period accruals end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million december recorded contra asset includes adjustments medical devices segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million december recorded contra assetincome taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates total tax effect repatriation would approximately billion current enacted tax laws regulations current currency exchange rates fiscal first quarter internal revenue service published final regulations addressing requirements tax deductibility settlement payments company recorded pretax reserve billion fiscal based agreement principle settle opioid litigation recorded additional pretax billion fiscal third quarter upon effective rate applied see note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated see notes consolidated financial statements information regarding product liability legal proceedings longlived intangible assets company assesses changes qualitatively quantitatively economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets mortality rates expected salary increases health care cost trend rates attrition rates see note consolidated financial statements details rates stock based compensation company recognizes compensation expense associated issuance equity instruments employees services based type equity instrument fair value estimated date grant using either blackscholes option valuation model combination blackscholes option valuation model monte carlo valuation model expensed financial statements service period input assumptions used determining fair value expected life expected volatility riskfree rate expected dividend yield prior fiscal performance share units fair market value calculated three component goals date grant operational sales adjusted operational earnings per share relative total shareholder return beginning fiscal performance share units fair market value calculated two component goals date grant adjusted operational earnings per share relative total shareholder return fair values earnings per share goal performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issuedaccounting pronouncements yet adopted january economic market factors covid considerations business continuity company considered various internal external factors assessing potential impact covid business financial results based upon information available time follows operating model company diversified business model across healthcare industry flexibility designed manufacturing research development clinical operations commercial capabilities supply chain company continues leverage global manufacturing footprint dualsource capabilities closely monitoring maintaining critical inventory major distribution centers away highrisk areas ensure adequate effective distribution business continuity robust active business continuity plans across company 's network instrumental preparing company events like covid ability meet majority patient consumer needs remains uninterrupted workforce company put procedures place protect essential workforce manufacturing distribution commercial research operations ensuring appropriate remote working protocols established employees liquidity company 's highquality credit rating allows company superior access financial capital markets foreseeable future fiscal third quarter company issued approximately billion commercial paper approximately billion outstanding year end additional liquidity additionally fiscal third quarter company issued senior unsecured notes total billion net proceeds offering used fund momenta pharmaceuticals inc acquisition october general corporate purposes domestic foreign legislation company continue assess evaluate ongoing global legislative efforts combat covid impact economies sectors participates currently recent legislative acts put place expected material impact companys operations fiscal company entered series contract manufacturing arrangements vaccine production third party contract manufacturing organizations arrangements provide company future supplemental commercial capacity vaccine production potentially transferable rights production capacity required amounts paid contractually obligated paid contract manufacturing organizations approximately billion reflected prepaid expenses assets accrued liabilities liabilities accounts company 's consolidated balance sheet upon execution agreement additionally company entered certain vaccine development cost sharing arrangements government related organizations company aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns company longstanding policy pricing products responsibly period us weighted average compound annual growth rate companys net price increases health care products prescription overthe counter drugs hospital professional products us consumer price index cpi company operates certain countries economic conditions continue present significant challenges company continues monitor situations take appropriate actions inflation rates continue effect worldwide economies consequently way companies operate company accounted operations argentina beginning fiscal third quarter venezuela highly inflationary prior threeyear cumulative inflation rate surpassed material impact company 's results period face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases june united kingdom uk held referendum voters approved exit european union eu commonly referred brexit uk officially exited eu january however transition period allow time agree terms new trade deal december uk eu european atomic energy community euratom signed euuk trade cooperation agreement tca last years brexit created global political economic uncertainty led volatility exchange rates interest rates additional cost containment thirdparty payors changes regulations uk eu agreed future trade cooperation agreement still unclear ultimate financial trade regulatory legal implications withdrawal uk eu however company currently believe related effects material impact companys consolidated financial position operating results january business companys uk subsidiaries represented less companys consolidated assets less company 's fiscal twelve months revenues company exposed fluctuations currency exchange rates change value us dollar compared foreign currencies company sales income expense would increased ordecreased translation foreign sales approximately million net income approximately million governments around world consider various proposals make changes tax laws may include increasing decreasing existing statutory tax rates change statutory tax rate country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes statutory tax rate may occur time related expense benefit recorded may material fiscal quarter year law change enacted company faces various worldwide health care changes may continue result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement health care products changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage result current global economic downturn may continue impact companys businesses company also operates environment increasingly hostile intellectual property rights firms filed abbreviated new drug applications biosimilar biological product applications fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset also risk one competitors could launch generic biosimilar version product issue following regulatory approval even though one valid patents place legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated january company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period see note consolidated financial statements information regarding legal proceedings common stock companys common stock listed new york stock exchange symbol jnj february record holders common stock company item quantitative qualitative disclosures market risk information called item incorporated herein reference item managements discussion andanalysis results operations financial condition liquidity capital resources financing market risk report note summary significant accounting policies financial instruments notes consolidated financial statements included item report item financial statements supplementary data index audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements comprehensive income consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm managements report internal control financial reporting johnson johnson subsidiaries consolidated balance sheets january december dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes prepaid expenses receivables assets held sale note total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income note total current liabilities longterm debt note deferred taxes income note employee related obligations notes longterm taxes payable note liabilities total liabilities commitments contingencies note shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income loss note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development note interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings net earnings per share notes basic diluted average shares outstanding notes basic diluted see notes consolidated financial statements johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service credit cost net amortization gain loss net amortization effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income tax effects comprehensive income fiscal years respectively foreign currency translation million million million employee benefit plans million million million derivatives hedges million million million see notes consolidated financial statements johnson johnson subsidiaries consolidated statements equity dollars millions note accumulated common stock treasury retained comprehensive issued stock total earnings income loss amount amount balance december cumulative adjustment net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january see note consolidated financial statements additional details effect cumulative adjustments retained earnings see notes consolidated financial statements johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation asset writedowns contingent consideration reversal net gain sale assetsbusinesses deferred tax provision credit losses accounts receivable allowances changes assets liabilities net effects acquisitions divestitures decreaseincrease accounts receivable increase inventories increase accounts payable accrued liabilities increase current noncurrent assets increasedecrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assetsbusinesses net acquisitions net cash acquired note purchases investments sales investments credit support agreements activity net primarily licenses milestones net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt repayment shortterm debt proceeds longterm debt net issuance costs repayment longterm debt proceeds exercise stock optionsemployee withholding tax stock awards net credit support agreements activity net net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest interest net amount capitalized income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds employee withholding tax stock awards conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net cash paid acquisitions note see notes consolidated financial statements notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated columns rows within tables may add due rounding percentages calculated using actual nonrounded figures description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer health previously referred consumer pharmaceutical medical devices consumer health segment includes broad range products used baby care oral care skin healthbeauty overthecounter pharmaceutical womens health wound care markets products marketed general public sold online ecommerce retail outlets distributors throughout world pharmaceutical segment focused six therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery interventional solutions cardiovascular neurovascular eye health fields distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics new accounting standards recently adopted accounting standards asu collaborative arrangements company adopted standard beginning fiscal year update clarifies interaction asc collaborative arrangements asc revenue contracts customers update clarifies certain transactions participants collaborative arrangement accounted asc counterparty customer addition update precludes entity presenting consideration transaction collaborative arrangement revenue counterparty customer transaction adoption standard material impact company 's consolidated financial statements asu financial instruments credit losses company adopted standard beginning fiscal year update introduces current expected credit loss cecl model requires entity measure credit losses certain financial instruments financial assets including trade receivables update initial recognition reporting period entity required recognize allowance reflects entitys current estimate credit losses expected incurred life financial instrument adoption standard material impact company 's consolidated financial statements asu compensation defined benefit plans company adopted standard fiscal year ended standard revised financial statement note disclosure requirements asc defined benefit plan sponsors adoption standard impact company 's consolidated financial statements see note consolidated financial statements defined benefit plan disclosuresaccounting standards adopted fiscal cumulative effect opening balance retained earnings following table summarizes cumulative effect adjustments made opening balance retained earnings upon adoption accounting standards cumulative effect adjustment increase decrease retained dollars millions earnings asu revenue contracts customers asu financial instruments asu income taxes intraentity transfers total recently issued accounting standards adopted january company assesses adoption impacts recently issued accounting standards financial accounting standards board company 's financial statements well material updates previous assessments companys annual report fiscal year ended december new material accounting standards issued fiscal impacted company cash equivalents company classifies highly liquid investments stated maturities three months less date purchase cash equivalents highly liquid investments stated maturities greater three months date purchase current marketable securities company policy making investments commercial institutions least investment grade credit rating company invests cash primarily government securities obligations corporate debt securities money market funds reverse repurchase agreements rras rras collateralized deposits form government securities obligations amount less value company record asset liability company permitted sell repledge associated collateral company policy collateral least equivalent credit rating company utilizes third party custodian manage exchange funds ensure collateral received maintained value rras daily basis rras stated maturities greater three months date purchase classified marketable securities investments investments classified held maturity investments reported amortized cost realized gains losses reported earnings investments classified availableforsale debt securities carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income availableforsale securities available current operations classified current assets otherwise classified long term management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company reviews investments impairment adjusts investments fair value earnings required property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events orchanges operating economic conditions occur impairment assessment may performed recoverability carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted variable consideration recorded reduction sales liability recognized within accrued rebates returns promotions consolidated balance sheet product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served significant portion liability related rebates sale company 's pharmaceutical products within us primarily managed care medicare medicaid programs amounted billion billion january december respectively company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer health pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal years promotional programs product listing allowances cooperative advertising arrangements recorded period related sales continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers years presented profitshare payments less total revenues included sales customers see note consolidated financial statements disaggregation revenue shipping handling shipping handling costs incurred billion billion billion fiscal years respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost net realizable value determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset abandoned point intangible asset written partially impaired intangible assets finite useful lives continue amortized useful lives reviewed forimpairment warranted economic conditions see note details intangible assets goodwill financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments leases company determines whether arrangement lease contract inception establishing contract conveys right control use identified property plant equipment period time exchange consideration right use rou assets lease liabilities operating leases included assets accrued liabilities liabilities consolidated balance sheet rou assets represent right use underlying asset lease term lease liabilities represent obligation make lease payments arising lease commitments finance leases significant included property plant equipment loans notes payable longterm debt consolidated balance sheet rou assets lease liabilities recognized lease commencement date based present value minimum lease payments lease term company uses incremental borrowing rate based information available commencement date determining present value lease payments implicit rate readily determinable lease terms may include options extend terminate lease options included lease term reasonably certain company exercise option operating lease expense recognized straightline basis lease term company elected following policy elections adoption use portfolio approach leases assets master service agreements exclusion short term leases balance sheet separating lease nonlease components company primarily operating lease space vehicles manufacturing equipment data processing equipment rou asset pertaining operating leases billion billion respectively lease liability billion billion respectively operating lease costs billion billion billion respectively cash paid amounts included measurement lease liabilities billion billion respectively product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information actuarially determined estimates applicable accruals adjusted periodically additional information becomes available company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated research development research development expenses expensed incurred accordance asc research development upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two partieswho active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including research development marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product profit share payments received sales customers royaltiesmilestones paid collaborative partner post cost products sold regulatory approval royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner research development expense preregulatory approval research development payments collaborative partner research development expense research development payments received reduction research development expense collaborative partner government entity milestones capitalized intangible assets amortized cost products sold useful life years presented individual project represented greater total annual consolidated research development expense company number products compounds developed collaboration strategic partners including xarelto codeveloped bayer healthcare ag imbruvica developed collaboration comarketed pharmacyclics llc abbvie company separately company number licensing arrangements products compounds including darzalex licensed genmab advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion fiscal years respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position united states enacted law new us tax legislation us tax cuts jobs act tcja law included provisions comprehensive overhaul corporate income tax code including reduction statutory corporate tax rate effective january tcja included provision tax previously undistributed earnings us companies located foreign jurisdictions undistributed earnings form cash cash equivalents taxed rate earnings taxed rate tax payable years accrue interest payments began continue remaining balance end approximately billion billion classified noncurrent reflected longterm taxes payable companys balance sheet balance account related receivables tax authorities expected received next months tcja also includes provisions tax global intangible lowtaxed income gilti gilti described excess us shareholders total net foreign income deemed return tangible assets provided tcja january fasb issued guidance allows companies elect accounting policy whether record tax effects gilti period tax liability generated ie period cost provide deferred tax assets liabilities related basis differences exist expected effect amount gilti inclusion future years upon reversal ie deferred method company elected account gilti deferred method deferred tax amounts recorded based evaluation temporary differences expected reverse gilti incurred future periods company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates total tax effect repatriation would approximately billion current enacted tax laws regulations current currency exchange rates see note consolidated financial statements information regarding income taxes net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes withholding taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued extent covid impacts companys business financial results depend numerous evolving factors including limited magnitude duration covid extent impact worldwide macroeconomic conditions including interest rates employment rates health insurance coverage speed anticipated recovery governmental business reactions pandemic company assessed certain accounting matters generally require consideration forecasted financial information context information reasonably available company unknown future impacts covid january date report accounting matters assessed included limited companys allowance doubtful accounts credit losses inventory related reserves accrued rebates associated reserves carrying value goodwill longlived assets material impact companys consolidated financial statements fiscal year ended january companys future assessment magnitude duration covid well factors could result material impacts companys consolidated financial statements future reporting periods annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks therefore includes additional shipping days case fiscal year case fiscal year reclassification certain prior period amounts reclassified conform current year presentation cash cash equivalents current marketable securities end fiscal year cash cash equivalents current marketable securities comprised dollars millions current carrying unrecognized estimated cash cash marketable amount gain fair value equivalents securities cash nonus sovereign securities us reverse repurchase agreements corporate debt securities money market funds time deposits subtotal us gov't securities sovereign securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities dollars millions current carrying cash cash marketable amount equivalents securities cash nonus sovereign securities us reverse repurchase agreements reverse repurchase agreements corporate debt securities money market funds time deposits subtotal gov't securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities held maturity investments reported amortized cost realized gains losses reported earnings available sale debt securities reported fair value unrealized gains losses reported net taxes comprehensive income end fiscal year carrying amount estimated fair value fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs contractual maturities available sale debt securities january follows cost basis fair value dollars millions due within one year due one year five years due five years ten years total debt securities company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least investment grade credit rating inventories end fiscal years inventories comprised dollars millions raw materials supplies goods process finished goods total inventories see note consolidated financial statements details assets held sale related divestitures fiscal year ended december assets held sale january property plant equipment end fiscal years property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net see note consolidated financial statements details assets held sale related divestitures fiscal year ended december assets held sale january company capitalizes interest expense part cost construction facilities equipment interest expense capitalized fiscal years million million million respectively depreciation expense including amortization capitalized interest fiscal years billion billion billion respectively upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings intangible assets goodwill end fiscal years gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net majority comprised customer relationships fiscal year company completed multiple acquisitions recorded inprocess research development intangible assets billion momenta pharmaceuticals inc billion bermekimab certain related assets xbiotech inc billion acquisition outstanding shares verb surgical inc goodwill january december allocated segment business follows dollars millions consumer health pharmaceutical medical devices total goodwill december goodwill related acquisitions currency translationother goodwill december goodwill related acquisitions currency translationother goodwill january weighted average amortization period patents trademarks years weighted average amortization period customer relationships intangible assets years amortization expense amortizable assets included cost products sold billion billion billion tax fiscal years ended january december december respectively intangible asset writedowns included income expense net estimated amortization expense approved products tax five succeeding years approximately dollars millions see note consolidated financial statements additional details related acquisitions divestitures fair value measurements company uses forward foreign exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany products thirdparty purchases materials denominated foreign currency company uses cross currency interest rate swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses interest rate swaps instrument manage interest rate risk related fixed rate borrowings derivatives designated fair value hedges company uses cross currency interest rate swaps forward foreign exchange contracts designated net investment hedges additionally company uses forward foreign exchange contracts offset exposure certain foreign currency assets liabilities forward foreign exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features company maintains credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements january total amount cash collateral paid company csa amounted billion net related net investment cash flow hedges ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company primarily enters agreements commercial institutions least investment grade credit rating refer table significant financial assets liabilities measured fair value contained footnote receivables payables commercial institutions january company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps billion billion respectively december company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective foreign exchange contracts designated cash flow hedges accounted forward method gainslosses associated contracts recognized income statement hedged item impacts earnings changes fair value derivatives recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gains losses associated interest rate swaps changes fair value hedged debt attributable changes interest rates recorded interest expense period occur effect immaterial fiscal years ended january december gains losses net investment hedge accounted currency translation account within accumulated comprehensive income portion excluded effectiveness testing recorded interest income expense using spot method ongoing basis company assesses whether derivative continues highly effective offsetting changes hedged items derivative longer expected highly effective hedge accounting discontinued company designated euro denominated notes issued may due dates ranging net investment hedge company 's investments certain international subsidiaries use euro functional currency order reduce volatility caused changes exchange rates january balance deferred net gain derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amounts related forward foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate contracts net investment hedges amount ultimately realized earnings may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative following table summary activity related derivatives hedges fiscal years ended january december net tax january december cost interest cost interest products rd income income products rd income income sales sold expense expense expense sales sold expense expense expense dollars millions effects fair value net investment cash flow hedging gain loss net investment hedging relationship cross currency interest rate swaps contracts amount gain loss recognized income derivative amount excluded effectiveness testing amount gain loss recognized aoci gain loss cash flow hedging relationship forward foreign exchange contracts amount gain loss reclassified aoci income amount gain loss recognized aoci cross currency interest rate swaps contracts amount gain loss reclassified aoci income amount gain loss recognized aoci following table effect derivatives designated hedging instrument fiscal years ended january december location gain loss gainloss recognized income recognized dollars millions derivative income derivative derivatives designated hedging instruments january december income expense foreign exchange contracts following table effect net investment hedges fiscal years ended january december gainloss location gain loss reclassified gainloss reclassified recognized accumulated accumulated oci accumulated oci comprehensive income income income january december january december dollars millions debt interest income expense cross currency interest rate swaps interest income expense company holds equity investments readily determinable fair values equity investments without readily determinable fair values company measures equity investments readily determinable fair values cost minus impairment plus minus changes resulting observable price changes orderly transactions identical similar investment issuer following table summary activity related equity investments fiscal years ended january december december january changes fair sales value reflected non current purchasesother dollars millions carrying value net income carrying value assets equity investments readily determinable value equity investments without readily determinable value december december changes fair sales value reflected non current purchasesother dollars millions carrying value net income carrying value assets equity investments readily determinable value equity investments without readily determinable value recorded incomeexpense includes impact currency fiscal years ended january december equity investments without readily determinable market values million million respectively changes fair value reflected net income result impairments million million respectively changes fair value reflected net income due changes observable prices fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability accordance asc threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward foreign exchange contracts interest rate contracts aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level debt securities classified level company holds acquisition related contingent liabilities based upon certain regulatory commercial events classified level whose values determined using discounted cash flow methodologies similar techniques determination fair value requires significant judgment estimations following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs companys significant financial assets liabilities measured fair value fiscal year ended january december follows dollars millions level level level total total derivatives designated hedging instruments assets forward foreign exchange contracts interest rate contracts total liabilities forward foreign exchange contracts interest rate contracts total derivatives designated hedging instruments assets forward foreign exchange contracts liabilities forward foreign exchange contracts available sale investments equity investments debt securities liabilities contingent consideration gross net derivative reconciliation dollars millions total gross assets credit support agreement csa total net asset total gross liabilities credit support agreement csa total net liabilities summarized information changes liabilities contingent consideration follows dollars millions beginning balance changes estimated fair value additions payments ending balance assets liabilities classified level exception equity investments million classified level contingent consideration million classified level includes million noncurrent assets december includes cross currency interest rate swaps interest rate swaps classified noncurrent assets classified cash equivalents current marketable securities includes million million primarily related auris health million classified noncurrent liabilities january december december respectively includes million million classified current liabilities january december respectively ongoing fair value adjustment amounts recorded primarily research development expense company recorded contingent consideration reversal million related timing certain developmental milestones associated auris health acquisition reversal contingent consideration recorded income expense see notes financial assets liabilities held carrying amount consolidated balance sheet borrowings components longterm debt follows effective effective rate rate dollars millions zero coupon convertible subordinated debentures due debentures due notes due notes due notes due notes due notes due b euro b euro notes due debentures due notes due notes due notes due mm euro mm euro notes due mm gbp mm gbp notes due notes due notes due notes due notes due notes due mm euro mm euro notes due notes due notes due debentures due notes due notes due b euro b euro notes due notes due notes due debentures due notes due debentures due notes due notes due notes due notes due notes due notes due notes due notes due subtotal less current portion total longterm debt weighted average effective rate translation rate january translation rate december excess fair value carrying value debt billion end fiscal year billion end fiscal year fiscal third quarter company issued senior unsecured notes total billion fair value longterm debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either bids provided banks london interbank offered rates libor secured overnight financing rate sofr swap curve applicable market rate allowed plus applicable margins commitment fees agreements material throughout fiscal year company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end fiscal year billion current portion longterm debt remainder commercial paper local borrowings international subsidiaries throughout fiscal year company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end fiscal year billion current portion long term debt remainder principally represents local borrowing international subsidiaries aggregate maturities longterm debt obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income includes billion deferred tax expense adoption deferred method account gilti comparison income tax expense us statutory rate fiscal years companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations us taxes international income tax benefits capital loss tax benefits sharebased compensation tcja related impacts effective rate periods presented company subsidiaries operating puerto rico various tax incentives international operations reflects impacts operations jurisdictions statutory tax rates different us particularly ireland switzerland puerto rico favorable impact effective tax rate compared us statutory rate amounts include impact new tax legislation enactment switzerland described includes impact gilti tax foreignderived intangible income deduction foreign income taxable us tax code represents impact adjustments balances originally recorded part tcja provisional tax charge information provided certain prior year amounts reclassified conform current year presentation fiscal year tax rate decreased compared fiscal year tax rate primarily driven following items fiscal year switzerland enacted federal act tax reform ahv financing traf became effective january federal transitional provisions traf allow companies certain conditions adjust tax basis certain assets fair value ie stepup depreciated amortized resulting incremental swiss tax deduction transitional period traf also provides parameters enable swiss cantons establish localized tax rates regulations companies new cantonal tax parameters include favorable tax benefits patents additional research development tax deductions cantonal transitional provisions traf allowed companies elect either tax basis stepup similar federal transition benefit alternative statutory tax rate period exceed years company currently operations located various swiss cantons fiscal year described detail company recorded impacts traf enacted period fiscal year final canton company maintains significant operations enacted traf legislation additionally company received rulings swiss federal cantonal tax authorities remaining jurisdictions significant operations rulings resulted company revising estimate tax basis adjustment ie stepup assets result company recorded additional deferred tax benefits company recognized net benefit fiscal year swiss tax reform approximately billion benefit companys annual effective tax rate comprised following items approximately billion tax benefit relating remeasurement swiss deferred tax assets liabilities change federal cantonal tax rates enactment occurred fiscal year benefit reflected international operations companys effective tax rate reconciliation million deferred tax asset related estimated value federal tax basis stepup companys swiss subsidiaries assets described benefit reflected international operations companys effective tax rate reconciliation approximately billion us deferred tax expense relating gilti deferred tax liability resulting remeasurement swiss deferred tax assets liabilities fiscal year benefit reflected us tax international income companys effective tax rate reconciliation company expect receive future rulings regarding transitional provisions trafalso fiscal fourth quarter company recognized capital loss certain us affiliates related previously impaired book value certain intangibles reduced tax rate approximately reflected tax benefits capital loss effective tax rate reconciliation addition fiscal year company lower income higher tax jurisdictions primarily driven impact accrual litigation costs related talc billion reduced us earnings taxes effective tax rate accrual additional legal costs including additional billion associated revised agreement principle settle opioid litigation effective tax rate company also generated additional tax benefits stockbased compensation either exercised vested reduced contingent consideration liability related auris health acquisition see note reversal unrecognized tax benefits due completion several years tax examinations certain jurisdictions fiscal year fiscal year tax rate decreased compared fiscal year tax rate addition impact traf discussed detail primary drivers net decrease follows company reorganized ownership structure certain whollyowned international subsidiaries fiscal fourth quarter resulted reduction certain withholding local taxes previously recognized part provisional tax cuts jobs act tcja tax charge fiscal year finalized fiscal year following completion restructuring approval applicable local authorities company reversed deferred tax liability billion related deferred tax asset billion us foreign tax credits net deferred tax benefit billion decreasing annual effective tax rate benefit reflected tcja related impacts companys effective tax rate reconciliation impact agreement principle settle opioid litigation billion see note consolidated financial statements reduced us earnings taxes effective tax rate decreased companys annual effective tax rate approximately december fiscal year us treasury issued final foreign tax credit regulations resulted company revising amount foreign tax credits initially recorded fiscal year part provisional tcja tax charge result company recorded increased deferred tax asset related foreign tax credits approximately billion annual effective tax rate benefit reflected tcja related impacts companys effective tax rate reconciliation company reassessed uncertain tax positions related current irs audit increased unrecognized tax benefit billion liability increased annual effective tax rate approximately see section unrecognized tax benefits additional information positions related uncertain tax regarding international transfer pricing expense classified international operations companys effective tax rate reconciliation subsequent december company received agreed notices proposed adjustments nopas irs company believes adequately reserved potential exposures several onetime tax impacts resulted cumulative net tax benefit annual effective tax rate items included lifescan divestiture adjustment provisional tcja tax charge acceleration certain tax deductions part tax return income higher tax jurisdictions relative lower tax jurisdictions compared described swiss tax legislation fiscal year company recorded net tax expense billion increased effective tax rate fiscal year approximately net tax expense related federal certain cantonal enactments fiscal year consisting following provisions approximately billion tax expense relating remeasurement swiss deferred tax assets liabilities change federal cantonal tax rates enactment occurred december expense reflected international operations companys effective tax rate reconciliation billion deferred tax asset related estimated value federal tax basis stepup companys swiss subsidiaries assets benefit reflected international operations companys effective tax rate reconciliation approximately million us deferred tax expense relating gilti deferred tax liability resulting remeasurement swiss deferred tax assets liabilities new deferred tax asset federalstepup benefit reflected us tax international income companys effective tax rate reconciliation fiscal year company completed full assessment finalized accounting impact tcja company recorded net adjustments components provisional charge approximately billion revisions based updated estimates additional analysis management well applying interpretative guidance issued us department treasury facts circumstances existed tcja enactment date charge primarily related additional deferred tax liabilities foreign local withholding taxes remaining balance undistributed foreign earnings december provided provisional charge described note fiscal year company elected treat gilti period expense deferred method recorded deferred tax cost approximately billion fiscal year related facts circumstances existed date tcja enactment company reorganized ownership structure certain foreign subsidiaries resulted reduction certain foreign withholding taxes recognized part provisional tcja tax charge fourth quarter following completion restructuring result clarification swiss tax authorities regarding applicability withholding tax repatriation certain earnings company reversed deferred tax liability billion related deferred tax asset billion us foreign tax credits net deferred tax benefit billion benefit reflected tcja related impacts companys effective tax rate reconciliation temporary differences carryforwards end fiscal years follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation amortization nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes net operating loss carryforward international undistributed foreign earnings global intangible lowtaxed income miscellaneous international miscellaneous us total deferred income taxes certain prior year amounts reclassified conform current year presentation company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries generate future taxable income sufficient utilize deferred tax assets following table summarizes activity related unrecognized tax benefits dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year unrecognized tax benefits billion january recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits progress number tax authorities respect united states internal revenue service irs completed auditfor tax years december company classified unrecognized tax benefits related interest approximately billion current liability accrued taxes income line consolidated balance sheet fiscal year company made final payments approximately billion us treasury related final settlement tax audit liability major jurisdictions company conducts business years remain open tax audit go back year company believes possible tax audits may completed next twelve months taxing authorities jurisdictions outside united states however company able provide reasonably reliable estimate timing future tax payments relating uncertain tax positions company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities except previously noted amounts related current united states irs audit interest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest expense million million million fiscal years respectively total amount accrued interest million million fiscal years respectively employee related obligations end fiscal fiscal employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant us nonunion pension benefits employees hired january primarily based employees compensation last five years retirement number years service final average pay formula us pension benefits employees hired calculated using different formula based employee compensation total years service retirement value formula january company announced effective january eligible us nonunion employees regardless hire date earn benefits retirement value formula amendment affect benefits accrued final average pay formula service january impact change decreases pbo january approximately billion included amendments line change benefit obligation international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company used december december respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost recognized actuarial losses gains curtailments settlements net periodic benefit cost unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains losses us benefit plans determined using corridor greater market value assets accumulated postretirement benefit obligation total unamortized gains losses excess corridor amortized average remaining future service prior service costsbenefits us pension plans amortized average remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendmentthe following table represents weightedaverage actuarial assumptions retirement plans benefit plans worldwide benefit plans net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation levels expected longterm rate return plan assets benefit obligation discount rate rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities company 's methodology determining service interest cost uses duration specific spot rates along yield curve plans ' liability cash flows expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate following table sets forth information related benefit obligation fair value plan assets fiscal yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year january company announced effective january eligible us nonunion employees regardless hire date earn benefits retirement value formula amendment affect benefits accrued final average pay formula service january actuarial losses retirement plans primarily related decreases discount rates company offered voluntary lumpsum payment option certain eligible former employees vested participants us qualified defined benefit pension plan distribution lumpsums completed end fiscal amount distributed approximately million retirement plans benefit plans dollars millions amounts recognized net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rates total lossincome recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december december respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans following table displays projected future minimum contributions unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest net asset value nav based value underlying assets owned fund minus liabilities divided number shares outstanding financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investment funds cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using nav provided administrator fund nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs equity securities equity securities valued closing price reported major market individual securities traded substantially equity securities classified within level valuation hierarchy commingled funds investment vehicles valued using nav provided fund administrator assets level category quoted market price assets assets represented primarily limited partnerships investment vehicles valued using nav provided fund administrator assets exchange listed actively traded classified level inactively traded assets classified level following table sets forth retirement plans ' investments measured fair value december december quoted prices significant active significant investments markets observable unobservable measured net identical assets inputs inputs asset value level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds assets investments fair value activity level assets significant years presented company 's benefit plans unfunded except us commingled funds level million million december december respectively us shortterm investment funds level million december fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible total company matching contributions plans million million million fiscal years respectively capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance january aggregate shares common stock issued approximately shares end fiscal years cash dividends paid per share fiscal year compared dividends per share fiscal year per share fiscal year january board directors declared regular cash dividend per share payable march shareholders record february december company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock share repurchase program completed september accumulated comprehensive income loss components comprehensive income loss consist following total gain accumulated foreign loss currency gainloss employee derivatives comprehensive dollars millions translation securities benefit plans hedges income loss december cumulative adjustment retained earnings net changes december net changes december net changes january per adoption asu financial instruments amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details comprehensive income see consolidated statements comprehensive income details reclassifications accumulated comprehensive income gainloss securities reclassifications released income expense net employee benefit plans reclassifications included net periodic benefit cost see note additional detailsgainloss derivatives hedges reclassifications earnings recorded account hedged transaction see note additional details international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency majority company 's subsidiaries local currency functional currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income current non current assets line within statement cash flows includes impact foreign currency translation equity account includes results translating certain balance sheet assets liabilities current exchange rates accounts historical rates except located highly inflationary economies argentina venezuela translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes fiscal years foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million fiscal years respectively earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended january december december millions except per share amounts basic net earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted net earnings per share diluted net earnings per share calculation fiscal year excluded million shares related stock options exercise price options greater average market value january company convertible debt diluted net earnings per share calculation fiscal year excluded insignificant number shares related stock options exercise price options greater average market value companys stock diluted net earnings per share calculation fiscal year included dilutive effect convertible debt offset related reduction interest expense million aftertax diluted net earnings per share calculation fiscal year included shares related stock options exercise price options less average market value company 's stock diluted net earnings per share calculation fiscal year included dilutive effect convertible debt offset related reduction interest expense million aftertax common stock stock option plans stock compensation agreements january company stockbased compensation plans shares outstanding contracts company 's longterm incentive plan longterm incentive plan longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan longterm incentive plan company may issue million shares common stock plus shares canceled expired forfeited issued longterm incentive plan subsequent april shares available future grants longterm incentive plan million end fiscal year compensation cost charged income plans million million million fiscal years respectively total income tax benefit recognized income statement sharebased compensation costs million million million fiscal years respectively company also recognized additional income tax benefits million million million fiscal years respectively options exercised restricted shares vested total unrecognized compensation cost million million million fiscal years respectively weighted average period cost recognized years years years fiscal years respectively sharebased compensation costs capitalized part inventory insignificant periods company settles employee benefit equity issuances treasury shares treasury shares replenished market purchases throughout year number shares used settle employee benefit equity issuances stock options stock options expire years date grant vest service periods range months years options granted average high low prices companys common stock new york stock exchange date grant fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table grants expected volatility represents blended rate year weekly historical overall volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted fiscal years respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years expected dividend yield summary option activity plan january december december changes years ending dates presented aggregate weighted intrinsic outstanding average exercise value shares thousands shares price dollars millions shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares january total intrinsic value options exercised million million million fiscal years respectively following table summarizes stock options outstanding exercisable january outstanding exercisable shares thousands weighted weighted average average exercise price range options average life exercise price options exercise price average contractual life remaining years stock options outstanding december december average life years average life years respectively stock options exercisable december december average price average price respectively restricted share units performance share units company grants restricted share units vest service periods range months years company also grants performance share units paid shares johnson johnson common stock end threeyear performance period whether performance share units vest amount vest tied completion service periods range months years achievement threeyear period three equallyweighted goals directly align help drive longterm total shareholder return operational sales adjusted operational earnings per share relative total shareholder return beginning fiscal performance shares granted two equallyweighted goals directly align help drive longterm total shareholder return adjusted operational earnings per share relative total shareholder return number shares actually earned end threeyear period vary based actual performance target number performance share units granted summary restricted share units performance share units activity plans january presented outstanding outstanding restricted share performance share units units shares thousands shares december granted issued canceledforfeitedadjusted shares january average fair value restricted share units granted fiscal years respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units issued million million million respectively weighted average fair value performance share units granted fiscal years calculated using weighted average fair market value component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model fair value performance share units issued million million million fiscal years respectively segments business geographic areas sales customers change dollars millions vs vs consumer health otc us international worldwide skin healthbeauty us international worldwide oral care us international worldwide baby care us international worldwide women 's health us international worldwide wound careother us international worldwide total consumer health us international worldwide previously referred consumer previously referred beauty pharmaceutical immunology us international worldwide remicade us us exports international worldwide simponi simponi aria us international worldwide stelara us international worldwide tremfya us international worldwide immunology us international worldwide infectious diseases us international worldwide edurant rilpivirine us international worldwide prezista prezcobix rezolsta symtuza us international worldwide infectious diseases us international worldwide neuroscience us international worldwide concerta methylphenidate us international worldwide invega sustenna xeplion invega trinza trevicta us international worldwide risperdal consta us international worldwide neuroscience us international worldwide oncology us international worldwide darzalex us international worldwide erleada us international worldwide imbruvica us international worldwide velcade us international worldwide zytiga abiraterone acetate us international worldwide oncology us international worldwide pulmonary hypertension us international worldwide opsumit us international worldwide uptravi us international worldwide us international worldwide cardiovascular metabolism us international worldwide xarelto us international worldwide invokana invokamet us international worldwide procrit eprex us international worldwide us international worldwide total pharmaceutical us international worldwide medical devices diabetes care us international worldwide interventional solutions us international worldwide orthopaedics us international worldwide hips us international worldwide knees us international worldwide trauma us international worldwide spine sports us international worldwide surgery us international worldwide advanced us international worldwide general us international worldwide vision us international worldwide contact lenses us international worldwide surgical us international worldwide total medical devices us international worldwide worldwide us international worldwide previously referred spine certain prior year amounts reclassified conform current year presentation percentage greater meaningful income loss tax identifiable assets dollars millions consumer health pharmaceutical medical devices total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer health pharmaceutical medical devices segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant fiscal year company utilized three wholesalers distributing products three segments represented approximately total consolidated revenues fiscal year company three wholesalers distributing products three segments represented approximately total consolidated revenues fiscal year company three wholesalers distributing products three segments represented approximately total consolidated revenues amounts allocated segments include interest income expense general corporate income expense general corporate includes cash cash equivalents marketable securities consumer health includes litigation expense billion primarily talc related reserves certain settlements pharmaceutical includes litigation expense billion primarily related agreement principle settle opioid litigation unrealized gain securities billion restructuring related charge billion medical devices includes contingent consideration reversal billion related timing certain developmental milestones associated auris health acquisition litigation expense billion restructuring related charge billion inprocess research development expense billion medical device regulation charge billion consumer health includes gain billion related company 's previously held equity investment dr cilabo litigation expense billion restructuring related charge billion pharmaceutical includes litigation expense billion billion related agreement principle settle opioid litigation inprocess research development expense billion related alios asset research development expense billion upfront payment related argenx unrealized gain securities billion actelion acquisition integration related costs billion restructuring charge billionmedical devices includes gain billion divestiture asp business restructuring related charge billion litigation expense billion auris health acquisition integration related costs billion consumer health includes gain billion divestiture nizoral litigation expense billion pharmaceutical includes inprocess research development charge billion related alios xo assets corresponding xo contingent liability reversal billion actelion acquisition integration related costs billion unrealized loss securities billion gain billion divestiture certain nonstrategic pharmaceutical products medical devices includes litigation expense billion restructuring related charge billion amo acquisition integration related costs billion gain billion divestiture lifescan business longlived assets include property plant equipment net fiscal years respectively intangible assets goodwill net fiscal years respectively acquisitions divestitures certain businesses acquired billion cash billion liabilities assumed fiscal year acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill fiscal year acquisitions primarily included rights investigational compound bermekimab multiple dermatological indications along certain employees xbiotech inc xbiotech momenta pharmaceuticals inc momenta company discovers develops novel therapies immunemediated diseases outstanding shares verb surgical inc company significant robotics data science capabilities fiscal first quarter company completed acquisition rights investigational compound bermekimab multiple dermatological indications along certain employees xbiotech inc purchase price billion fair value acquisition allocated primarily nonamortizable intangible assets primarily iprd billion applying probability success factor ranged reflect inherent development regulatory commercial risk different indications discount rate applied approximately xbiotech may eligible receive additional payments upon receipt certain commercialization authorizations transaction accounted business combination included pharmaceutical segment additionally fiscal first quarter company completed acquisition outstanding shares verb surgical inc company significant robotics data science capabilities including shares previously held verily transaction accounted business combination included medical devices segment fair value acquisition allocated primarily nonamortizable intangible assets primarily iprd billion goodwill billion assets billion liabilities assumed billion fair value company 's previously held equity investment verb surgical inc billion october company completed acquisition momenta purchase price approximately billion net cash acquired fair value acquisition allocated primarily nonamortizable intangible assets iprd billion goodwill billion assets billion liabilities billion assets acquired intended address substantial unmet medical need maternalfetal disorders neuroinflammatory disorders rheumatology dermatology autoimmune hematology depending asset probability success factors ranging used fair value calculation reflect inherent development regulatory risk iprd thediscount rate applied approximately goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes transaction accounted business combination included pharmaceutical segment fiscal year certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill fiscal year acquisitions primarily included dr cilabo japanese company focused marketing development distribution broad range dermocosmetic cosmetic skincare products auris health inc privately held developer robotic technologies initially focused lung cancer fdacleared platform currently used bronchoscopic diagnostic therapeutic procedures january company acquired dr cilabo japanese company focused marketing development distribution broad range dermocosmetic cosmetic skincare products total purchase price approximately billion equates approximately billion using exchange rate japanese yen us dollar january additionally fiscal first quarter company recognized pretax gain recorded income expense net approximately billion related company 's previously held equity investment dr cilabo company treated transaction business combination included consumer health segment fiscal first quarter company finalized purchase price allocation final fair value acquisition allocated primarily amortizable intangible assets billion goodwill billion liabilities billion amortizable intangible assets comprised brandtrademarks customer relationships weighted average life years goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes april company completed acquisition auris health inc approximately billion net cash acquired additional contingent payments billion aggregate may payable upon reaching certain predetermined milestones auris health privately held developer robotic technologies initially focused lung cancer fdacleared platform currently used bronchoscopic diagnostic therapeutic procedures company treated transaction business combination included medical devices segment fair value acquisition allocated primarily amortizable nonamortizable intangible assets primarily iprd billion goodwill billion marketable securities billion liabilities assumed billion includes fair value contingent payments mentioned fiscal second quarter company finalized purchase price allocation fiscal company recorded income approximately billion reversal contingent consideration related timing certain developmental commercial milestones expected met based companys current timelines fiscal third quarter company recorded partial iprd impairment charge billion related timing progression digital surgery platforms probability success factor ranging used fair value calculation reflect inherent regulatory commercial risk contingent payments iprd discount rate applied approximately goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes fiscal year certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill accordance us gaap standards related business combinations goodwill intangible assets supplemental pro forma information fiscal years provided impact aforementioned acquisitions material effect companys results operations cash flows financial position divestitures subsequent fiscal separate transactions company divested two brands outside us within pharmaceutical segment received combined proceeds approximately billion company reflect brand divestitures financial results fiscal year company sold million shares idorsia ltd idorsia ownership company transaction resulted gross proceeds approximately chf million million based sales price chf share immaterial net loss company currently rights least additional million shares approximately idorsia equity convertible loan principal amount chf million due june idorsia also access approximate chf million credit facility company january idorsia made drawdowns credit facility fiscal year company divested asp business fortive corporation aggregate value ofapproximately billion consisting billion cash proceeds billion retained net receivables company recognized pretax gain recorded income expense net approximately billion fiscal year company divested lifescan inc business approximately billion retained certain net liabilities divestitures fiscal year included nizoral roc certain nonstrategic pharmaceutical products pretax gains divestitures approximately billion fiscal year company accepted binding offer form strategic collaboration jabil inc one worlds leading manufacturing services providers health care products technology products company expanding year relationship jabil produce range products within ethicon endosurgery depuy synthes businesses transaction includes transfer employees manufacturing sites transfers completed fiscal year january assets held sale consolidated balance sheet december assets held sale consolidated balance sheet billion inventory property plant equipment net additional details global supply chain restructuring see note consolidated financial statements legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial supplier indemnification matters governmental investigations legal proceedings arise time time ordinary course business due ongoing impacts covid pandemic certain trials rescheduled delayed company continues monitor legal proceedings situation evolves company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated january company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period product liability johnson johnson certain subsidiaries involved numerous product liability claims lawsuits involving multiple products claimants cases seek substantial compensatory available punitive damages company believes substantial defenses feasible predict ultimate outcome litigation time time even substantial defenses company considers isolated settlements based variety circumstances company established accruals product liability claims lawsuits compliance asc based currently available information cases may limited company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated certain matters company accrued additional amounts estimated costs associated settlements damages losses product liability accruals represent projected product liability thousands claims around world different litigation environments different fact patterns changes accruals may required future additional information becomes availablethe significant cases include depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic meshes risperdal xarelto body powders containing talc primarily johnsons baby powder invokana ethicon physiomesh flexible composite mesh january united states approximately plaintiffs direct claims pending lawsuits regarding injuries allegedly due depuy asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic meshes respect risperdal respect xarelto respect body powders containing talc respect invokana respect ethicon physiomesh flexible composite mesh august depuy orthopaedics inc depuy announced worldwide voluntary recall asr x l acetabular system depuy asr h ip resurfacing system used hip replacement surgery claims personal injury made depuy johnson johnson number pending lawsuits expected fluctuate certain lawsuits settled dismissed additional lawsuits filed cases filed federal courts united states organized multi district litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia ireland germany india italy november depuy reached agreement courtappointed committee lawyers representing asr hip system plaintiffs establish program settle claims eligible asr hip patients united states surgery replace asr hips known revision surgery august depuy reached additional agreements february march extended settlement program include asr hip patients revision surgeries august prior february settlement program resolved claims therefore bringing resolution significant asr hip litigation activity united states however lawsuits united states remain settlement program address litigation outside united states australia class action settlement reached resolved claims majority asr hip patients country canada company reached agreements settle class actions filed country company continues receive information respect potential additional costs associated recall worldwide basis company established accruals costs associated united states settlement program depuy asr h iprelated product liability litigation claims personal injury also made depuy orthopaedics inc johnson johnson collectively depuy relating pinnacle acetabular cup system used hip replacement surgery product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court northern district texas litigation also filed state courts countries outside united states several adverse verdicts rendered depuy one reversed appeal remanded retrial first quarter depuy established united states settlement program resolve cases part settlement program adverse verdicts settled company established accrual product liability litigation associated pinnacle acetabular cup system related settlement program claims personal injury made ethicon inc ethicon johnson johnson arising ethicon 's pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse company continues receive information respect potential costs additional cases cases filed federal courts united states organized multidistrict litigation mdl united states district court southern district west virginia mdl court remanding cases trial jurisdictions case originally filed additional pelvic mesh lawsuits filed remain outside mdl company settled otherwise resolved majority united states cases estimated costs associated settlements remaining cases reflected company 's accruals addition class actions individual personal injury cases claims commenced various countries outside united states including claims cases united kingdom netherlands class actions israel australia canada seeking damages alleged injury resulting ethicon 's pelvic mesh devices november federal court australia issued judgment regarding findings respect liability relation three lead applicants generally relation design manufacture pre postmarket assessments testing supply promotion devices australia used treat stress urinary incontinence pelvic organ prolapse march court entered damages awards three lead applicants company appealing decision respect group members individual case assessment process require proof use causally related loss form individual case assessment process yet determined court class actions canada discontinued result settlement group cases company established accruals respect product liability litigation associated ethicon 's pelvic mesh product following june worldwide market withdrawal ethicon physiomesh flexible composite mesh claims personal injury made ethicon inc johnson johnson alleging personal injury arising use hernia mesh device cases filed federal courts united states organized multidistrict litigation mdl united states district court northern district georgia multicounty litigation mcl also beenformed new jersey state court assigned atlantic county cases pending new jersey addition matters mdl mcl additional lawsuits pending united states district court southern district ohio part mdl polypropylene mesh devices manufactured cr bard inc lawsuits pending outside united states discovery proceeding cases certain cases preparation trials claims also filed ethicon johnson johnson alleging personal injuries arising proceed mesh proceed ventral patch hernia mesh products march new jersey supreme court entered order consolidating cases pending new jersey mcl atlantic county superior court additional cases filed various federal state courts us jurisdictions outside us discovery underway cases september plaintiffs attorney filed application new jersey supreme court seeking centralized management prolene polypropylene hernia system phs cases new jersey supreme court granted plaintiffs application january cases also transferred mcl atlantic county superior court discovery underway cases company established accruals respect product liability litigation associated ethicon physiomesh flexible composite mesh proceed mesh proceed ventral patch prolene polypropylene hernia system products claims personal injury made janssen pharmaceuticals inc johnson johnson arising use risperdal related compounds indicated treatment schizophrenia acute manic mixed episodes associated bipolar disorder irritability associated autism lawsuits primarily filed state courts pennsylvania california missouri actions pending various courts united states canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company successfully defended number cases verdicts company including verdict october billion punitive damages related one single plaintiff subsequently reduced january million trial judge company plaintiff appealing judgment company settled otherwise resolved many united states cases costs associated settlements reflected company 's accruals claims personal injury arising use xarelto oral anticoagulant made janssen pharmaceuticals inc jpi johnson johnson jj jpis collaboration partner xarelto bayer ag certain affiliates cases filed federal courts united states organized multidistrict litigation united states district court eastern district louisiana addition cases filed state courts across united states many cases consolidated state mass tort litigation philadelphia pennsylvania coordinated proceeding los angeles california class action lawsuits also filed canada march jpi jj announced agreement principle settle xarelto cases united states settlement agreement executed may settlement became final december settlement funded january resolved majority cases pending united states company established accruals costs associated united states settlement program xarelto related product liability litigation personal injury claims alleging talc causes cancer made johnson johnson consumer inc johnson johnson arising use body powders containing talc primarily johnsons baby powder number pending personal injury lawsuits continues increase company continues receive information respect potential costs anticipated number cases lawsuits primarily filed state courts missouri new jersey california suits also filed outside united states majority cases pending federal court organized multidistrict litigation mdl united states district court district new jersey mdl parties sought exclude experts daubert motions april court issued rulings limit scope testimony including theories testing methods certain plaintiff expert witnesses denied plaintiffs attempt limit scope testimony certain companys witnesses ruling made casespecific discovery begun per courts directive talc cases previously gone trial company obtained defense verdicts number also verdicts company many reversed appeal june missouri court appeals reversed part affirmed part july verdict billion ingham v johnson johnson et al ed mo app reducing overall award billion additional interest january company pursues appeal currently billion ingham decision application transfer case missouri supreme court subsequently denied company currently seeking review united states supreme court company continues believe strong legal grounds appeal verdict well verdicts appealed notwithstanding companys confidence safety talc products certain circumstances company may settle cases company established accrual defense costs reserves resolution ofcertain cases claims including ingham decision currently appeal connection product liability litigation associated body powders containing talc february companys talc supplier imerys talc america inc two affiliates imerys talc vermont inc imerys talc canada inc collectively imerys filed voluntary chapter petition commencing reorganization united states bankruptcy code united states bankruptcy court district delaware imerys bankruptcy imerys bankruptcy relates imerys potential liability personal injury exposure talcum powder sold imerys talc claims bankruptcy filing imerys noted certain claims alleges company indemnification rights joint insurance proceeds company previously proposed resolve imerys ' companys obligations arising talc claims agreeing assume defense litigation talc claims involving company 's products waiving companys indemnification claims imerys lifting automatic stay enable talc claims proceed outside bankruptcy forum company agreeing settle pay judgment imerys may imerys asbestos claimants committee plan proponents filed plan reorganization plan disclosure statement related thereto agreeing put north american operations auction subsequently amended company objected disclosure statement intends object plan reorganization currently structured additionally june cyprus mines corporation parent cyprus filed adversary proceeding company well imerys seeking declaration indemnity certain contractual agreements company denies indemnification owed filed motion dismiss adversary complaint arguing among things court subject matter jurisdiction cypruss claims company plan proponents filed numerous amendments plan disclosure statement company objected hearing plan proponents disclosure statement held january court entered order approving disclosure statement ninth amended joint chapter plan reorganization imerys talc america inc debtor affiliates allowing debtors proceed soliciting votes plan company intends continue object plan hearing consider confirmation plan scheduled june february securities class action lawsuit filed johnson johnson certain named officers united states district court district new jersey alleging johnson johnson violated federal securities laws failing disclose alleged asbestos contamination body powders containing talc primarily johnson 's baby powder purchasers johnson johnsons shares suffered losses result plaintiff seeking damages april company moved dismiss complaint briefing motion complete august december court denied part motion dismiss march defendants answered complaint discovery underway june shareholder filed complaint initiating summary proceeding new jersey state court books records inspection august johnson johnson responded books records complaint filed cross motion dismiss september plaintiff replied court heard oral argument court yet ruled books records action october december january four shareholders filed four separate derivative lawsuits johnson johnson nominal defendant current directors certain officers defendants united states district court district new jersey alleging breach fiduciary duties related alleged asbestos contamination body powders containing talc primarily johnsons baby powder johnson johnson suffered damages result alleged breaches february four cases consolidated single action caption johnson johnson talc stockholder derivative litigation july report delivered companys board directors independent counsel retained board investigate allegations derivative lawsuits series shareholder letters board received raising similar issues four shareholders sent demands plaintiffs th e johnson johnson talc stockholder derivative litigation independent counsel recommended company reject shareholder demands take steps necessary appropriate secure dismissal derivative lawsuits board unanimously adopted recommendations independent counsels report october shareholders filed consolidated complaint january johnson johnson moved dismiss consolidated complaint january two erisa class action lawsuits filed participants johnson johnson savings plan johnson johnson pension benefits committee certain named officers united states district court district new jersey alleging defendants breached fiduciary duties offering johnson johnson stock johnson johnson savings plan investment option imprudent failures disclose alleged asbestos contamination body powders containing talc primarily johnsons baby powder plaintiffs seeking damages injunctive relief september defendants filed motion dismiss april court granted defendants motion granted leave amend june plaintiffs filed amended complaint july defendants moved dismiss amended complaint october briefing defendants motion complete lawsuit pending superior court california county san diego alleging violations californias consumer legal remedies act relating johnsons baby powder resolved companys favor lawsuit plaintiffs allege johnson johnson violated clra failing provide required proposition warnings july company filed notice removal united states district court southern district california plaintiffs filed second amended complaint shortly thereafter october company moved dismiss second amended complaint failure state claim upon relief may granted response motions plaintiffs filed third amended complaint december company moved dismiss third amended complaint failure state claim upon relief may granted april court granted motion dismiss granted leave amend may plaintiffs filed fourth amended complaint indicated would filing motion leave file fifthamended complaint plaintiffs filed fifth amended complaint august company moved dismiss fifth amended complaint failure state claim upon relief may granted january court issued order opinion ruling companys favor granting motion dismiss prejudice january abtahi law group filed action proposition johnson johnson johnson johnson consumer inc well number alleged talcum powder manufacturers distributors including one california company action plaintiff alleges contamination talcum powder products unsafe levels arsenic hexavalent chromium lead plaintiff seeks civil penalties injunctive relief defendants filed motion summary judgment january hearing scheduled april limited informal discovery continuing addition company received preliminary inquiries subpoenas produce documents regarding matters senator murray member senate committee health education labor pensions department justice securities exchange commission sec us congressional subcommittee economic consumer policy company produced documents required response continue cooperate government inquiries november sec terminated investigation claims personal injury made number johnson johnson companies including janssen pharmaceuticals inc johnson johnson arising use invokana prescription medication indicated improve glycemic control adults type diabetes december lawsuits filed federal courts united states organized multidistrict litigation united states district court district new jersey cases also filed state courts class action lawsuits filed canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company settled otherwise resolved many cases claims united states costs associated settlements reflected company 's accruals claims personal injury made number johnson johnson companies including janssen pharmaceuticals inc johnson johnson arising use elmiron prescription medication indicated relief bladder pain discomfort associated interstitial cystitis lawsuits allege elmiron contributes development permanent retinal injury vision loss filed state federal courts across united states december federal cases including two putative class action cases seeking medical monitoring organized multidistrict litigation united states district court district new jersey addition three class action lawsuits filed canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company established accruals defense costs associated elmiron related product liability litigation intellectual property certain subsidiaries johnson johnson subject time time legal proceedings claims related patent trademark intellectual property matters arising businesses many matters involve challenges coverage andor validity patents various products allegations certain companys products infringe patents third parties although subsidiaries believe substantial defenses challenges allegations respect significant patents assurance outcome matters loss cases could adversely affect ability subsidiaries sell products result loss sales due loss market exclusivity require payment past damages future royalties may result noncash impairment charge associated intangible asset significant matters described medical devices november medidea llc medidea filed patent infringement lawsuit depuy orthopaedics inc united states district court northern district illinois alleging infringement attune knee system april medidea filed amended complaint adding depuy synthes products inc depuy synthes sales inc named defendants collectively depuy medidea alleged infringement united states patent nos relating posterior stabilized knee systems specifically medidea alleges sofcam tm contact feature attune posterior stabilized knee products infringes patentsinsuit medidea seeking monetary damages injunctive relief june case transferred united states district court district massachusetts november judgment entered favor depuy january us court appeals federal circuit affirmedin december dr ford albritton sued acclarent inc acclarent united states district court northern district texas alleging acclarents relieva spin relievea spinplus products infringe us patent dr albritton also alleges breach contract fraud true owner acclarents us patent trial scheduled begin october november board regents university texas system tissuegen inc collectively ut filed lawsuit united states district court western district texas ethicon inc ethicon us llc collectively ethicon alleging manufacture sale vicryl plus antibacterial sutures monocryl plus antibacterial sutures pds plus antibacterial sutures stratafix pds antibacterial sutures stratafix monocryl plus antibacterial sutures infringe plaintiffs united states patent nos directed implantable polymer drug releasing biodegradable fibers containing therapeutic agent ut seeking damages injunction december ethicon filed petitions united states patent trademark office uspto seeking inter partes review ipr asserted patents june uspto denied institution patent ipr granted institution patent ipr ut dismissed patent suit longer accuses pds plus antibacterial sutures stratafix pds plus antibacterial sutures infringement previously scheduled district court trial postponed august intuitive surgical inc intuitive surgical operations inc collectively intuitive filed patent infringement suit auris health inc auris united states district court district delaware suit intuitive alleges willful infringement us patent nos based auris monarch platform auris filed ipr petitions uspto regarding patents intuitive subsequently dropped patents suit december uspto instituted review patent denied review patent february march uspto instituted review patents denied review patent december uspto declared challenged claims patent invalid intuitive appealed decision district court trial scheduled begin june august rsb spine llc rsb spine filed patent infringement suit depuy synthes inc united states district court district delaware october rsb spine amended complaint change named defendants depuy synthes sales inc depuy synthes products inc suit rsb spine alleges willful infringement united states patent nos one following products zeropva spacer zerop spacer zerop natural plate synfix lr spacer synfix evolution system rsb spine seeks monetary damages injunctive relief november suit consolidated pretrial purposes patent infringement suits brought rsb spine united states district court district delaware life spine inc medacta usa inc precision spine inc june case stayed pending ipr proceedings filed consolidated defendants involving asserted patents march osteoplastics llc filed patent infringement suit depuy synthes inc depuy synthes products inc medical device business services inc synthes inc collectively depuy synthes united states district court district delaware suit osteoplastics alleges willful infringement us patent nos based proplan cmf virtual surgical planning services trumatch cmf personalize solutions april osteoplastics filed amended complaint substitute us patent us patent osteoplastics seeks monetary damages injunctive relief june depuy synthes filed motion dismiss complaint october court dismissed medical device business services inc case otherwise denied motion trial scheduled october pharmaceutical litigation filers abbreviated new drug applications andas following summarizes lawsuits pending generic companies filed andas fda undertaken similar regulatory processes outside united states seeking market generic forms products sold various subsidiaries johnson johnson prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity applicable patents event subsidiaries successful action automatic statutory stay andas expires united states district court rulings obtained thirdparty companies involved would ability upon approval fda introduce generic versions products market resulting potential substantial market share revenue losses applicable products may result noncash impairment charge associated intangible asset addition time time subsidiaries may settle types actions settlements involve introduction generic versions products issue market prior expiration relevant patents inter partes review ipr process theuspto created america invents act also used times generic companies conjunction andas lawsuits challenge applicable patents zytiga november janssen inc janssen oncology inc collectively janssen initiated notice application section patented medicines notice compliance regulations apotex inc apotex minister health canada response apotexs filing abbreviated new drug submission ands seeking approval market generic version zytiga expiration canadian patent final hearing concluded may october court issued order prohibiting canadian minister health approving apotexs ands expiration patent november apotex filed appeal beginning january janssen initiated statements claim section patented medicines notice compliance regulations canada apotex pharmascience inc pharmascience dr reddy 's laboratories ltd dr reddy 's laboratories inc collectively drl response parties filing abbreviated new drug submissions ands seeking approval market generic versions zytiga expiration patent final hearing actions concluded november court issued decision holding patent invalid january february janssen appealed decision august janssen initiated statement claim section patented medicines notice compliance regulations jamp pharma corporation jamp canada response jamps filing ands seeking approval market generic version zytiga expiration patent final hearing scheduled begin may canadian actions janssen seeking order enjoining defendants marketing generic versions zytiga expiration patent xarelto august janssen pharmaceuticals inc jpi bayer intellectual property gmbh bayer ag collectively bayer filed patent infringement lawsuit united states district court district new jersey dr reddys laboratories inc dr reddys laboratories ltd collectively drl filed anda seeking approval market generic version xarelto expiration us patent lawsuit jpi bayer seeking order enjoining drl marketing generic versions xarelto expiration relevant patents november jpi bayer entered confidential settlement agreement drl case voluntarily dismissed invokana invokamet invokamet xr beginning july janssen pharmaceuticals inc janssen research development llc cilag gmbh international janssen pharmaceutica nv collectively janssen mitsubishi tanabe pharma corporation mtpc filed patent infringement lawsuits united states district court district new jersey number generic companies filed andas seeking approval market generic versions invokana invokamet andor invokamet xr expiration mtpcs united states patent nos andor relating invokana invokamet andor invokamet xr janssen exclusive licensee asserted patents named defendants include msn laboratories private ltd msn pharmaceuticals inc msn zydus pharmaceuticals usa inc zydus sandoz inc sandoz lupin ltd lupin pharmaceuticals inc lupin cases consolidated one action polymorph main action scheduled trial starting april december janssen mtpc entered confidential settlement sandoz january janssen mtpc entered confidential settlement lupin cases sandoz lupin voluntarily dismissed july janssen mtpc filed patent infringement lawsuit united states district court district new jersey zydus filed andas seeking approval market generic versions invokana ivokamet expiration mtpcs united states patent andor relating invokana invokamet andor invokamet xr compounds main action janssen exclusive licensee asserted patents trial concluded october july janssen mtpc filed patent infringement lawsuit united states district court district new jersey msn filed anda seeking approval market generic version invokamet xr expiration patent patent relating invokamet xr october janssen mtpc initiated patent infringement lawsuit united states district court district new jersey msn filed andas seeking approval market generic versions invokana invokamet xr expiration patent october janssen mtpc initiated patent infringement lawsuit united states district court district new jersey dr reddys laboratories inc dr reddys laboratories ltd drl filed anda seeking approval market generic version invokamet expiration patent january janssen mtpc filed patent infringement lawsuit united states district court district new jersey macleods pharmaceuticals ltd macleods pharma usa inc macleods filed anda seeking approval market generic version invokamet xr expiration patent patent relating invokamet xr february janssen filed patent infringement lawsuit united states district court district new jersey macleods pharmaceuticals ltd macleods pharma usa inc macleods filed anda seeking approval market generic version invokana expiration united states patent relating invokana lawsuits consolidated main actions us lawsuits janssen mtpc seeking order enjoining defendant marketing generic versions invokana invokamet andor invokamet xr expiration relevant patents october janssen inc janssen pharmaceutica nv mtpc initiated statement claim section patented medicines notice compliance regulations sandoz canada inc sandoz canada response sandozs filing ands seeking approval market generic version invokana expiration canadian patent nos final hearing scheduled begin august janssen inc janssen pharmaceutica nv mtpc seeking order enjoining sandoz marketing generic version invokana expiration relevant patents opsumit n october actelion pharmaceuticals ltd actelion initiated patent infringement lawsuit united states district court district new jersey laurus labs limited pharmaq inc collectively laurus filed anda seeking approval market generic versions opsumit expiration us patent actelion seeking order enjoining laurus marketing generic versions opsumit expiration patent january actelion entered settlement agreement laurus may janssen inc janssen actelion initiated statement claim section patented medicines notice compliance regulations sandoz canada inc sandoz canada response sandozs filing ands seeking approval market generic version opsumit mg expiration canadian patent trial scheduled begin january may janssen actelion initiated statement claim section patented medicines notice compliance regulations apotex inc apotex canada response apotexs filing ands seeking approval market generic version opsumit mg expiration patent trial scheduled begin february july janssen actelion initiated statement claim section patented medicines notice compliance regulations jamp pharma corporation jamp canada response jamps filing ands seeking approval market generic version opsumit mg expiration patent canadian patent trial scheduled begin april canadian actions janssen actelion seeking order enjoining defendants marketing generic versions opsumit expiration relevant patents invega sustenna january janssen pharmaceutica nv janssen pharmaceuticals inc collectively janssen initiated patent infringement lawsuit united states district court district new jersey teva pharmaceuticals usa inc teva filed anda seeking approval market generic version invega sustenna expiration united states patent trial concluded october august janssen initiated patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan filed anda seeking approval market generic version invega sustenna expiration patent february mylan filed petition inter partes review uspto seeking invalidate patent uspto denied petition september mylan appealed december janssen initiated patent infringement lawsuit united states district courts districts new jersey delaware pharmascience inc mallinckrodt plc specgx llc collectively pharmascience filed anda seeking approval market generic version invega sustenna expiration patent us lawsuits janssen seeking order enjoining defendant marketing generic version invega sustenna expiration relevant patents february janssen inc janssen pharmaceutica nv collectively janssen canada initiated statement claim section patented medicines notice compliance regulations teva canada limited teva canada response teva 's filing ands seeking approval market generic version invega sustenna expiration canadian patent nos janssen subsequently discontinued portion lawsuit relating patent may canadian federal court issued public judgment reasons declaring teva canadas generic version invega sustenna approved would infringe claims patent claims patent invalid obviousness teva canada appealed november janssen canada initiated statement claim section patented medicines notice compliance regulations pharmascience inc response pharmascience inc 's filing ands seeking approval market generic version invega sustenna expiration patent final hearing scheduled begin july january janssen canada initiated statement claim section patented medicines notice compliance regulations apotex inc apotex response apotex 's filing ands seeking approval market generic version invega sustenna expiration patent final hearing scheduled begin september canadian lawsuits janssen canada seeking order enjoining defendant marketing generic version invega sustenna expiration relevant patents imbruvica beginning january pharmacyclics llc pharmacyclics janssen biotech inc jbi filed patent infringement lawsuits united states district court district delaware number generic companies filed andas seeking approval market generic versions imbruvica mg capsules expiration pharmacyclics united states patent nos andor relating imbruvica jbi exclusive licensee asserted patents named defendants include following generic companies cipla limited cipla usa inc collectively cipla sandoz inc lek pharmaceuticals dd collectively sandoz january pharmacyclics jbi amended complaint sandoz allege infringement united states patent nos february pharmacyclics jbi amended complaint cipla allege infringement united states patent nos march pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware alvogen pine brook llc natco pharma ltd collectively alvogen filed anda seeking approval market generic versions imbruvica tablets asserting infringement united states patent nos may pharmacyclics jbi amended complaint cipla allege infringement united states patent june pharmacyclics jbi amended complaint alvogen allege infringement united states patent august pharmacyclics jbi amended complaints cipla sandoz allege infringement us patent nos august court granted joint stipulation stay litigation cipla trial actions sandoz alvogen took place october march sandoz filed ipr petition uspto seeking invalidate united states patent september uspto issued final decision ipr invalidating certain claims patent upholding validity certain claims patent final decision appealed parties march pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware alvogen sandoz asserting infringement united states patent april pharmacyclics jbi amended complaint sandoz allege infringement us patent october pharmacyclics jbi amended complaint sandoz allege infringement us patent nos amended complaint alvogen allege infringement us patent december court entered joint stipulation dismissing complaint sandoz april pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware zydus worldwide dmcc cadila healthcare limited collectively zydus filed anda seeking approval market generic versions imbruvica tablets asserting infringement united states patent nos trials actions alvogen zydus scheduled begin march lawsuits pharmacyclics jbi seeking order enjoining defendants marketing generic versions imbruvica expiration relevant patents uptravi april actelion pharmaceuticals ltd actelion nippon shinyaku co ltd nippon shinyaku initiated patent infringement lawsuit united states district court district new jersey number generic companies filed andas seeking approval market generic versions uptravi expiration nippon shinyakus united states patent nos relating uptravi actelion exclusive licensee asserted patents defendants include alembic pharmaceuticals limited alembic pharmaceuticals inc collectively alembic msn laboratories private limited msn pharmaceuticals inc collectively msn vgyaan pharmaceuticals llc vgyaan zydus pharmaceuticals usa inc zydus worldwide dmcc collectively zydus january court entered joint stipulations dismissing vgyaan msn suit actelion nippon shinyaku seeking order enjoining defendants marketing generic versions uptravi expiration relevant patents invega trinza september janssen pharmaceuticals inc janssen pharmaceutica nv janssen research development lcc collectively janssen initiated patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan pharmaceuticals inc mylan institutional llc collectively mylan mylan filed anda seeking approval market generic versions invega trinza expiration united states patent relating invega trinza janssen seeking order enjoining mylan marketing generic version invega trinza expiration relevant patent government proceedings like companies pharmaceutical consumer health medical devices industries johnson johnson certain subsidiaries subject extensive regulation national state local government agencies united states countries operate regulation basis government investigations litigations significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigationaverage wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries jj awp defendants along numerous pharmaceutical companies named defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue payors alleged used awps calculating provider reimbursement levels plaintiffs cases included three classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp many cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation united states district court district massachusetts claims jj awp defendants ultimately dismissed jj awp defendants also prevailed case brought commonwealth pennsylvania awp cases resolved court order settlement case brought illinois settled trial new jersey putative class action based upon awp allegations pending centocor inc ortho biotech inc janssen biotech inc johnson johnson alza corporation cases resolved opioid litigation beginning continuing present johnson johnson janssen pharmaceuticals inc jpi along pharmaceutical companies named lawsuits related marketing opioids including duragesic nucynta nucynta er suits also raise allegations related previously owned active pharmaceutical ingredient supplier subsidiaries tasmanian alkaloids pty ltd noramco inc subsidiaries divested majority cases filed state local governments similar lawsuits also filed private plaintiffs organizations including limited following individual plaintiffs behalf children suffering neonatal abstinence syndrome hospitals health insurerspayors date complaints pharmaceutical companies including johnson johnson jpi filed state attorneys general arkansas florida idaho illinois kentucky louisiana mississippi missouri new hampshire new jersey new mexico new york ohio oklahoma south dakota texas washington west virginia complaints manufacturers also filed state federal court city county local government agencies following states alabama arizona arkansas california connecticut florida georgia illinois kentucky louisiana maine maryland massachusetts mississippi missouri nevada new hampshire new jersey new mexico new york north carolina ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah virginia washington west virginia wisconsin government puerto rico filed suit superior court san juan cases pending various state courts federal cases coordinated federal multidistrict litigation mdl pending us district court northern district ohio mdl addition province british columbia filed suit canada october antitrust complaint filed private plaintiffs federal court tennessee pending transfer mdl actions allege variety claims related opioid marketing practices including false advertising unfair competition public nuisance consumer fraud violations deceptive acts practices false claims unjust enrichment suits generally seek penalties andor injunctive monetary relief suits plaintiffs seeking joint several liability among defendants adverse judgment lawsuits could result imposition large monetary penalties significant damages including punitive damages cost abatement substantial fines equitable remedies sanctions trial matter filed oklahoma attorney general resulted judgment johnson johnson jpi amount million subject final order issued court court issued final judgment reducing amount million johnson johnson jpi appealed judgment company believes strong grounds overturn judgment october johnson johnson jpi announced settlement first case set trial mdl two counties ohio johnson johnson jpi pharmaceutical companies also received subpoenas requests information related opioids marketing practices following state attorneys general alaska indiana montana new hampshire south carolina tennessee texas washington september johnson johnson jpi contacted texas colorado attorney generals offices behalf approximately states regarding multistate attorney general investigation october company announced proposed agreement principle would include company paying billion settlement matters october company agreed contribute additional billion allin settlement amount would resolve opioid lawsuits filed future claims states cities counties tribal governments total billion accrued subject various conditions agreement finalized agreement principle admission liability wrongdoing would resolve opioid lawsuits filed future claims states cities counties company predict agreement finalized andindividual cases ongoing august johnson johnson received grand jury subpoena united states attorneys office eastern district new york documents related companys antidiversion policies procedures distribution opioid medications company understands part broader investigation manufacturers distributors monitoring programs reporting controlled substances act september johnson johnson received subpoenas new york state department financial services nydfs part industrywide inquiry effect opioid prescriptions new york health insurance premiums september company learned nydfs filed statement charges related investigation june december companys board directors received series shareholder demand letters alleging breaches fiduciary duties related marketing opioids board retained independent counsel investigate allegations demands n april independent counsel delivered report board recommending company reject shareholder demands take steps necessary appropriate secure dismissal related derivative litigation board unanimously adopted recommendations independent counsels report november one shareholders sent demand filed derivative complaint johnson johnson nominal defendant certain current former directors officers defendants superior court new jersey complaint alleges breaches fiduciary duties related marketing opioids johnson johnson suffered damages result alleged breaches may shareholder filed amended complaint challenging boards rejection demand august johnson johnson moved dismiss amended complaint december motion fully briefed august another shareholder sent demand filed separate derivative complaint court making similar allegations october court granted defendants request reassign secondfiled case division firstfiled case pending december two additional shareholders sent demands filed two separate derivative complaints making similar allegations johnson johnson nominal defendant certain current former directors officers defendants united states district district new jersey april two federal cases consolidated single action captioned johnson johnson opioid stockholder derivative litigation july shareholders filed consolidated complaint september johnson johnson moved dismiss consolidated complaint december shareholders opposed johnson johnsons motion johnson johnson filed reply february july additional shareholder sent demand filed derivative complaint federal court making similar allegations defendants named consolidated action january pursuant order consolidated action third case consolidated consolidated action february shareholders consolidated action filed motion voluntary dismissal august depuy orthopaedics inc depuy inc known depuy synthes inc johnson johnson services inc collectively depuy received informal request united states attorney 's office district massachusetts civil division united states department justice united states production materials relating depuy asr xl hip device july united states notified united states district court district massachusetts declined intervene qui tam case filed pursuant false claims act companies february district court granted companies motion dismiss prejudice unsealed qui tam complaint denied qui tam relators request leave file amended complaint qui tam relators appealed case united states court appeals first circuit july first circuit affirmed district courts dismissal part reversed part affirmed decision deny relators request file third amended complaint relators remaining claims pending district court july court ordered relators complete discovery august relators requested extension august deadline depuy opposed additional discoveryrelated motions filed parties additionally depuy requested schedule filing motion strike dismiss relators second amended complaint october johnson johnson contacted california attorney general 's office regarding multistate attorney general investigation marketing surgical mesh products hernia urogynecological purposes johnson johnson 's subsidiary ethicon inc ethicon may california washington filed civil complaints johnson johnson ethicon ethicon us llc alleging violations consumer protection statutes similar complaints filed companies following states kentucky mississippi west virginia oregon april johnson johnson ethicon settled washington case california case started trial july concluded september trial date kentucky case scheduled september adjourned new trial date scheduled october johnson johnson ethicon settled multistate investigation states district columbia january court california issued statement decision finding favor state ofcalifornia awarded civil penalties amount million april court california denied company 's motion new trial august court entered judgment respect penalties million denied attorney generals request injunctive relief company appealing penalty judgment april company settled west virginia october company settled attorney general oregon november company settled attorney general mississippi december therakos inc therakos formerly subsidiary johnson johnson part orthoclinical diagnostics inc ocd franchise received letter civil division united states attorney 's office eastern district pennsylvania informing therakos united states attorney 's office investigating sales marketing uvadex methoxsalen uvar xts cellex systems period present united states attorney 's office requested ocd johnson johnson preserve documents could relate investigation therakos subsequently acquired affiliate gores capital partners iii lp january ocd divested june following divestiture ocd johnson johnson retained ocds portion liability resulting investigation activity occurred prior sale therakos following production documents settlement discussions us attorneys office jj affiliate medical device business services inc agreed resolve claims federal false claims act analogous state laws settlement announced november settlement agreement medical device business services expressly denied wrongful conduct result settlement qui tam complaint filed two relators pending us district court eastern district pennsylvania dismissed separate settlement agreements states participating settlement process finalized june mississippi attorney general filed complaint chancery court first judicial district hinds county mississippi johnson johnson johnson johnson consumer companies inc known johnson johnson consumer inc jjci complaint alleges defendants violated mississippi consumer protection act failing disclose alleged health risks associated female consumers ' use talc contained johnson 's baby powder johnson 's shower shower product divested seeks injunctive monetary relief matter stayed pending interlocutory appeal december denial johnson johnson jjci 's motion summary judgment mississippi supreme court granted jj jjci 's request file interlocutory appeal denial motion summary judgment late briefing complete oral argument held february january state new mexico filed consumer protection case alleging company deceptively marketed sold talcum powder products making misrepresentations safety products presence carcinogens including asbestos state new mexico filed amended complaint march company moved dismiss certain claims amended complaint granted company filed motion partial judgment pleadings december fortyone states commenced joint investigation companys marketing talcum powder products time multistate group asserted claims company several states issued civil investigative demands seeking documents information march janssen pharmaceuticals inc jpi received civil investigative demand united states attorneys office southern district new york related jpis contractual relationships pharmacy benefit managers period january present regard certain jpi 's pharmaceutical products demand issued connection investigation false claims act company provided documents response demand july johnson johnson janssen products lp served qui tam complaint pursuant false claims act filed united states district court district new jersey alleging offlabel promotion two hiv products prezista intelence antikickback violations connection promotion products complaint filed seal december federal state governments declined intervene lawsuit prosecuted relators february court stayed case ordered mediation march janssen biotech inc received civil investigative demand united states department justice regarding false claims act investigation concerning management advisory services provided rheumatology gastroenterology practices purchased remicade simponi aria august unites states department justice notified janssen biotech inc closing investigation subsequently united states district court district massachusetts unsealed qui tam false claims act complaint served company department justice declined intervene qui tam lawsuit august company filed motion dismiss granted part denied part discovery underwayin april september johnson johnson received subpoenas united states attorney district massachusetts seeking documents broadly relating pharmaceutical copayment support programs darzalex olysio remicade simponi stelara zytiga subpoenas also seek documents relating average manufacturer price best price reporting center medicare medicaid services related products well rebate payments state medicaid agencies company provided documents response subpoenas june johnson johnson received subpoena united states attorney 's office district massachusetts seeking information regarding practices pertaining sterilization depuy synthes inc spinal implants three hospitals boston well interactions employees company subsidiaries physicians hospitals johnson johnson depuy synthes inc produced documents response subpoena fully cooperating governments investigation july public prosecution service rio de janeiro representatives brazilian antitrust authority cade inspected offices companies including johnson johnson brasil indstria e comrcio de produtos para sade ltda authorities appear investigating allegations possible anticompetitive behavior possible improper payments medical device industry continue actively respond inquiries regarding foreign corrupt practices act united states department justice united states securities exchange commission time time company received requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested information general litigation march purported class action filed circuit court third judicial district madison county illinois johnson johnson consumer inc jjci alleging violations state consumer fraud statutes based nondisclosure alleged health risks associated talc contained johnson 's baby powder complaint seeks damages allege personal injury october jjci moved dismiss complaint august united states customs border protection us cbp issued penalty notice janssen ortho llc janssen ortho assessing penalties alleged improper classification darunavir ethanolate active pharmaceutical ingredient prezista connection importation united states august us cbp formally rejected janssens supplemental petition challenging penalties assessment demanded payment mitigated penalty october us cbp agreed refer matter office chief counsel time pending resolution related classification litigation december janssen ortho sued united states united states court international trade classification litigation seeking determination darunavir ethanolate exempt duties upon importation united states february court ruled darunavir ethanolate eligible duty free treatment april united states appealed united states court appeals federal circuit september genmab brought arbitration janssen biotech inc pursuant license agreement parties arbitration relates royalties certain janssen daratumumab products march april putative class action complaints filed contact lens patients number courts around united states johnson johnson vision care inc jjvci contact lens manufacturers distributors retailers alleging vertical horizontal conspiracies fix retail prices contact lenses complaints allege manufacturers reached agreements certain distributors retailers concerning prices contact lenses could sold consumers plaintiffs seeking damages injunctive relief class action cases transferred united states district court middle district florida june plaintiffs filed consolidated class action complaint november discovery pretrial motion practice complete trial date set august two thirdparty payors filed purported class action united states district court eastern district louisiana janssen research development llc janssen ortho llc janssen pharmaceuticals inc orthomcneil janssen pharmaceuticals inc johnson johnson well certain bayer entities alleging defendants improperly marketed promoted xarelto safer effective less expensive alternative medications failing fully disclose risks complaint seeks damages november defendants moved dismiss complaint september pfizer inc pfizer filed antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania pfizer alleges janssen violated federal antitrust laws contracting strategies remicade complaint seeks damages injunctiverelief discovery ongoing beginning september multiple purported class actions filed behalf indirect purchasers remicade johnson johnson janssen biotech inc collectively janssen alleging janssen violated federal antitrust laws contracting strategies remicade cases consolidated pretrial purposes remicade antitrust litigation united states district court eastern district pennsylvania consolidated complaint seeks damages injunctive relief discovery ongoing june walgreen co kroger co filed antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania complaint alleges janssen violated federal antitrust laws contracting strategies remicade complaint seeks damages injunctive relief march summary judgment granted favor janssen february united states court appeals third circuit reversed district courts decision discovery ongoing june united states federal trade commission ftc issued civil investigative demand johnson johnson connection investigation whether janssens remicade contracting practices violate federal antitrust laws company produced documents information responsive civil investigative demand october certain united states service members families brought complaint number pharmaceutical medical devices companies including johnson johnson certain subsidiaries united states district court district columbia alleging defendants violated united states antiterrorism act complaint alleges defendants provided funding terrorist organizations sales practices pursuant pharmaceutical medical device contracts iraqi ministry health july district court dismissed complaint january plaintiffs appealed district courts decision united states court appeals district columbia circuit october two separate putative class actions filed actelion pharmaceutical ltd actelion pharmaceuticals us inc actelion clinical research inc collectively actelion united states district court district maryland united states district court district columbia complaints allege actelion violated state federal antitrust unfair competition laws allegedly refusing supply generic pharmaceutical manufacturers samples tracleer tracleer subject risk evaluation mitigation strategy required food drug administration imposes restrictions distribution product january plaintiffs dismissed district columbia case filed consolidated complaint united states district court district maryland october court granted actelions motion dismiss amended complaint plaintiffs appealed decision united states court appeals fourth circuit december janssen biotech inc janssen oncology inc janssen research development llc johnson johnson collectively janssen served qui tam complaint filed behalf united states states district columbia complaint filed december united states district court northern district california alleges janssen violated federal false claims act state law providing pricing information zytiga government connection direct government sales governmentfunded drug reimbursement programs time federal state governments declined intervene case transferred united states district court district new jersey september janssen moved dismiss complaint april blue cross blue shield louisiana hmo louisiana inc filed class action complaint janssen biotech inc janssen oncology inc janssen research development llc btg international limited united states district court eastern district virginia behalf indirect purchasers zytiga several additional complaints filed thereafter virginia new jersey indirect purchaser complaints generally allege defendants violated antitrust consumer protections laws several states sherman act pursuing patent litigation relating zytiga order delay generic entry seek damages virginia cases transferred united states district court district new jersey consolidated new jersey case pretrial purposes may class action complaint filed janssen biotech inc janssen oncology inc janssen research development llc btg international limited united states district court district new jersey behalf direct purchasers zytiga direct purchaser complaint alleges defendants violated sherman act pursuing patent litigation relating zytiga order delay generic entry seek damages injunctive relief may class action antitrust complaint filed janssen rd ireland janssen johnson johnson theunited states district court northern district california complaint alleges janssen violated federal state antitrust consumer protection laws agreeing exclusivity provisions agreements gilead concerning development marketing combination antiretroviral therapies cart treat hiv complaint also alleges gilead entered similar agreements bristolmyers squibb japan tobacco march court granted part denied part defendants motions dismiss plaintiffs filed amended complaint april defendants moved dismiss amended complaint july court granted part denied part renewed motion dismiss discovery ongoing october innovative health llc filed complaint biosense webster inc bwi united states district court middle district california complaint alleges certain bwis business practices contractual terms violate antitrust laws united states state california restricting competition sale high density mapping catheters ultrasound catheters january bwi filed motion dismiss complaint august court granted part denied part bwis motion dismiss discovery ongoing november johnson johnson received demand indemnification pfizer inc pursuant stock asset purchase agreement company pfizer also november johnson johnson inc received demand indemnification sanofi consumer health inc pursuant asset purchase agreement jj inc sanofi january johnson johnson received demand indemnification boehringer ingelheim pharmaceuticals inc pursuant asset purchase agreement among company pfizer boehringer ingelheim notices seek indemnification legal claims related overthecounter zantac ranitidine products plaintiffs underlying actions allege zantac overthecounter ranitidine medications contain unsafe levels ndma nnitrosodimethylamine cause andor caused various cancers patients using products seek injunctive monetary relief october fortis advisors llc fortis capacity representative former stockholders auris health inc auris filed complaint johnson johnson ethicon inc certain named officers employees collectively ethicon court chancery state delaware complaint alleges breach contract fraud causes action ethicon connection ethicons acquisition auris complaint seeks damages relief december ethicon moved dismiss certain causes action complaint johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation restructuring fiscal second quarter company announced plans implement series actions across global supply chain intended focus resources increase investments critical capabilities technologies solutions necessary manufacture supply product portfolio enhance agility drive growth global supply chain actions include expanding use strategic collaborations bolstering initiatives reduce complexity improve costcompetitiveness enhance capabilities optimize supply chain network additional details global supply chain restructuring strategic collaborations see note consolidated financial statements fiscal year company recorded pretax charge billion included following lines consolidated statement earnings billion restructuring billion income expense billion cost products sold total project costs approximately billion recorded since restructuring announced see following table additional details restructuring program total company expects global supply chain actions generate approximately billion billion annual pretax cost savings substantially delivered company expects record pretax restructuring charges approximately billion billion year period activity costs associated network optimizations exit costs accelerated depreciation amortization following table summarizes severance charges associated spending initiatives fiscal year ended asset write severance total offssales dollars millions reserve balance december activity reserve balance december current year activity charges cash settlements settled non cash reserve balance january cash outlays severance expected substantially paid next years accordance company 's plans local laws includes project expense salaries employees supporting initiatives consulting expenses relates pension related net actuarial losses associated transfer employees jabil inc part strategic collaboration represents gain sale asset company continuously reevaluates severance reserves related restructuring timing payments due planned release associates regarding several longerterm projects company believes existing severance reserves sufficient cover global supply chain plans given period actions take place company continue assess make adjustments necessary additional amounts become probable estimable report independent registered public accounting firm board directors shareholders johnson johnson opinions financial statements internal control financial reporting audited accompanying consolidated balance sheets johnson johnson subsidiaries company january december related consolidated statements earnings comprehensive income equity cash flows three fiscal years period ended january including related notes collectively referred consolidated financial statements also audited company 's internal control financial reporting january based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company january december results operations cash flows three fiscal years period ended january conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting january based criteria established internal control integrated framework issued coso basis opinions company 's management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinions companys consolidated financial statements company 's internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use ordisposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate critical audit matters critical audit matters communicated matters arising current period audit consolidated financial statements communicated required communicated audit committee relate accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate us pharmaceutical rebate reserves managed care medicare medicaid described note consolidated financial statements company recognizes revenue product sales obligations terms contract customer satisfied rebates discounts provided customers accounted variable consideration recorded reduction sales liability rebates discounts recognized within accrued rebates returns promotions consolidated balance sheet significant portion liability related rebates sale pharmaceutical goods within us primarily managed care medicare medicaid programs amounted billion january significant rebate programs include us managed care medicare medicaid rebate programs rebates discounts estimated management based contractual terms historical experience patient outcomes trend analysis projected market conditions us pharmaceutical market principal considerations determination performing procedures relating us pharmaceutical rebate reserves managed care medicare medicaid critical audit matter significant judgment management due significant measurement uncertainty involved developing reserves high degree auditor judgment subjectivity audit effort performing procedures evaluating assumptions related contractual terms historical experience patient outcomes trend analysis projected market conditions us pharmaceutical market addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating us pharmaceutical rebate reserves managed care medicare medicaid including controls assumptions used estimate rebates procedures also included among others developing independent estimate rebates utilizing third party information price market conditions us pharmaceutical market terms specific rebate programs historical experience trend analysis actual rebate claims paid ii testing rebate claims processed company including evaluating claims consistency contractual mandated terms companys rebate arrangements iii comparing independent estimates managements estimates litigation contingencies talc described notes consolidated financial statements company records accruals loss contingencies associated legal matters including talc probable liability incurred amount loss reasonably estimated extent adverse verdicts rendered company management record accrual loss determined probable reasonably estimated matters management unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved verdicts company matter including verdict july billion reversed part affirmed part missouri court appeals june reducing overall award billion additional interest january company pursues appeal currently billion application transfer case missouri supreme court subsequently denied company currently seeking review united states supreme court described management company continues believe strong legal grounds appeal verdict well verdicts appealed notwithstanding companys confidence safety talc products certain circumstances company may settle cases company established accrual defense costs reserves settlement ofcertain cases claims well one case currently appeal connection product liability litigation associated body powders containing talc principal considerations determination performing procedures relating talc litigation critical audit matter significant judgment management assessing likelihood loss incurred determining whether reasonable estimate loss range loss claim made turn led high degree auditor judgment subjectivity effort performing procedures evaluating managements assessment loss contingencies associated litigation addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating managements evaluation talc litigation including controls determining whether loss probable whether amount loss reasonably estimated well financial statement disclosures procedures also included among others gaining understanding companys process around accounting reporting talc litigation ii discussing status significant known actual potential litigation companys inhouse legal counsel well external counsel deemed necessary iii obtaining evaluating letters audit inquiry internal external legal counsel significant litigation iv evaluating reasonableness managements assessment regarding whether unfavorable outcome reasonably possible probable reasonably estimable v evaluating sufficiency companys litigation contingencies disclosures litigation opioids described notes consolidated financial statements company records accruals loss contingencies associated legal matters including opioids probable liability incurred amount loss reasonably estimated extent adverse verdicts rendered company management record accrual loss determined probable reasonably estimated matters management unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved company named numerous lawsuits brought certain state local governments related opioids matters trial matter filed oklahoma attorney general resulted judgment company amount million subsequently reduced million company appealed judgment described management believes strong grounds overturn judgment separately october company announced proposed agreement principle would include company paying billion settlement lawsuits october company agreed contribute additional billion allin settlement amount would resolve opioid lawsuits filed future claims states cities counties tribal governments total billion accrued subject various conditions agreement finalized described management agreement principle admission liability wrongdoing would resolve opioid lawsuits filed future claims states cities counties principal considerations determination performing procedures relating opioids litigation critical audit matter significant judgment management assessing likelihood loss incurred judgment company oklahoma determining whether reasonable estimate range loss proposed agreement principle settle opioids litigation made turn led high degree auditor judgment subjectivity effort performing procedures evaluating managements assessment loss contingencies associated litigation addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating managements evaluation opioid litigation including controls determining whether loss probable whether amount loss reasonably estimated well financial statement disclosures procedures also included among others gaining understanding companys process around accounting reporting opioids litigation ii discussing status significant known actual potential litigation ongoing settlement negotiations companys inhouse legal counsel well external counsel deemed necessary iii obtaining evaluating letters audit inquiry internal external legal counsel significant litigation iv evaluating reasonableness managements assessment regarding whether unfavorable outcome reasonably possible probable reasonably estimable v evaluating sufficiency companys litigation contingencies disclosuress pricewaterhousecoopers llp florham park new jersey february served companys auditor since least able determine specific year began serving auditor company managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting january making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based companys processes assessment described management concluded january companys internal control financial reporting effective effectiveness companys internal control financial reporting january audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein alex gorsky joseph j wolk alex gorsky joseph j wolk chairman board directors executive vice president chief financial officer chief executive officer shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending january cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure alex gorsky chairman chief executive officer joseph j wolk executive vice president chief financial officer reviewed participated evaluation based evaluation messrs gorsky wolk concluded end period covered report companys disclosure controls procedures effective reports internal control financial reporting information called item incorporated herein reference managements report internal control financial reporting attestation regarding internal controls financial reporting included report independent registered public accounting firm included item report changes internal control financial reporting fiscal quarter ended january changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting company experienced material impact internal controls financial reporting despite fact employees working remotely due covid pandemic company proactively took actions reevaluate refine financial reporting process additional monitoring controls provide reasonable assurance financial results reported accurately timely company continues monitor assess effectiveness design operation disclosure controls procedures company implementing multiyear enterprisewide initiative integrate simplify standardize processes systems human resources information technology procurement supply chain finance functions enhancements support growth companys financial shared service capabilities standardize financial systems initiative response identified deficiency weakness companys internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information applicable part iii item directors executive officers corporate governance information called item incorporated herein reference discussion audit committee caption item election directors board committees material captions item election directors applicable stock ownership section compliance delinquent section reports proxy statement material caption executive officers registrant part report companys code business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act code business conduct available companys website wwwjnjcomcode ofbusinessconduct copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code business conduct waiver code granted chief executive officer chief financial officer controller posted companys website atwwwinvestorjnjcomgovcfm within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys website wwwinvestorjnjcomgovboardconductcfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions item election directors director compensation item compensation committee report compensation discussion analysis executive compensation tables proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent company specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters information called item incorporated herein reference material caption item stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements item report equity compensation plan information following table provides certain information january concerning shares companys common stock may issued existing equity compensation plans number securities weighted issued upon average exercise exercise price number securities outstanding outstanding remaining available options options future issuance equity plan category rights rights compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders longterm incentive plan longterm incentive plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions item election directors director independence related person transactions proxy statement item principal accountant fees services information called item incorporated herein reference material caption item ratification appointment independent registered public accounting firm proxy statement part iv item exhibits financial statement schedules following documents filed part report financial statements consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements comprehensive income fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm schedules omitted applicable required information included financial statements notes exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report item summary registrants may voluntarily include summary information required item company elected include summary information signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant gorsky gorsky chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date gorsky chairman board directors february gorsky chief executive officer principal executive officer chief financial officer j j wolk february j j wolk principal financial officer controller chief accounting officer r j decker jr february r j decker jr principal accounting officer director c beckerle february c beckerle director davis february davis director e l davis february e l davis director j doudna february j doudna signature title date hewson director february hewson h joly director february h joly b mcclellan director february b mcclellan director mulcahy february mulcahy director c prince february c prince director e washington february e washington director weinberger february weinberger ny west director february n west director r williams february r williams exhibit indexreg sk exhibit table description item exhibit restated certificate incorporation effective february incorporated herein reference exhibit registrants annual report fiscal year ended january ii certificate amendment certificate incorporation johnson johnson effective april incorporated herein reference exhibit registrant 's form k current report filed april iii bylaws company amended effective june incorporated herein reference exhibit registrants form k current report filed june upon request securities exchange commission registrant furnish copy instruments defining rights holders longterm debt registrant b description securities registered pursuant section securities exchange act incorporated herein reference exhibit registrants form k current report filed august longterm incentive plan incorporated herein reference exhibit registrants registration statement filed may file b form stock option certificate longterm incentive plan incorporated herein reference exhibit registrants form k current report filed january c longterm incentive plan incorporated herein reference appendix registrants proxy statement filed march form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference exhibits registrants form q quarterly report quarter ended april e global nonqualified stock option award agreement global restricted share unit award agreement global performance share unit award agreement longterm incentive plan incorporated herein reference exhibits registrants form q quarterly report quarter ended april f johnson johnson executive incentive plan amended november incorporated herein reference exhibit registrants form q quarterly report quarter ended march g domestic deferred compensation certificate extra compensation plan incorporated herein reference exhibit g registrants annual report year ended december h amendments certificate extra compensation plan effective january incorporated herein reference exhibit j registrants annual report year ended december certificates longterm performance plan incorporated herein reference exhibit registrants form q quarterly report quarter ended september j amended restated deferred fee plan directors amended january incorporated herein reference exhibit k registrant 's annual report fiscal year ended january k johnson johnson executive income deferral plan amended restated effective january incorporated herein reference exhibit registrants form q quarterly report quarter ended september l excess savings plan effective january incorporated herein reference exhibit j registrants annual report fiscal year ended december amendments johnson johnson excess savings plan effective january incorporated herein reference exhibit p registrants annual report fiscal year ended december n amended restated excess benefit plan johnson johnson affiliated companies amended restated effective january except otherwise provided filed document executive life plan agreement incorporated herein reference exhibit registrants form k annual report fiscal year ended january p executive life plan agreement closure letter incorporated herein reference exhibit registrants form q quarterly report quarter ended march q employment agreement dr paulus stoffels incorporated herein reference exhibit registrants form q quarterly report quarter ended september reg sk exhibit table description item exhibit r severance pay plan johnson johnson us affiliated companies amended restated october incorporated herein reference exhibit registrant 's form q quarterly report quarter ended september first amendment severance pay plan johnson johnson us affiliated companies amended restated effective october incorporated herein reference exhibit registrant 's form q quarterly report quarter ended june second amendment severance pay plan johnson johnson us affiliated companies amended restated effective october incorporated herein reference exhibit x registrant 's annual report fiscal year ended january subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document certification chief financial officer pursuant section sarbanesoxley act furnished document exhibit exins instance document instance document appear interactive data file xbrl tags embedded within inline xbrl document exsch inline xbrl taxonomy extension schema excal inline xbrl taxonomy extension calculation linkbase exlab inline xbrl taxonomy extension label linkbase expre inline xbrl taxonomy extension presentation linkbase exdef inline xbrl taxonomy extension definition document exhibit cover interactive data filethe cover interactive data file appear interactive data file xbrl tags embedded within inline xbrl document management contract compensatory plan paper filing copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company pursuant item biiia regulation sk company filed exhibits certain longterm debt instruments including indentures total amount securities authorized exceed total assets company subsidiaries consolidated basis company hereby agrees furnish copy instrument sec upon request exhibit certification amendment restatement excess benefit plan johnson johnson affiliated companies restatement restatement excess benefit plan johnson johnson affiliated companies effective january except otherwise provided incorporates amendments adopted since january includes certain changes clarifications restatement approved pension benefits committee johnson johnson behalf pension benefits committee johnson johnson dated warren luther warren luther memberexcess benefit plan johnson johnson affiliated companies amended restated effective january except otherwise providedexcess benefit plan johnson johnson affiliated companies table contents pagearticle introduction article ii definitions beneficiary code controlled group crp employer erisa fap benefit fap formula grandfathered benefit participant payment start date pension benefits committee plan plan administrator pr plan qualified plan rvp formula separation service statutory limitations article iii eligibility participation eligibility period participation article iv benefits amount benefits time form payment automatic cashout small benefits rehired participants article v vesting article vi disability death disability death article vii unfunded plan plan assets tophat plan status article viii plan administration plan administrators powers delegation administrative authority engaging third parties assist plan administration privilege proof right receive benefits tax withholding claims procedures limitations forum selection article ix amendment termination amendment termination payments upon plan termination article x miscellaneous construction alienation transfer benefits section compliance scriveners error recovery overpayment address records controlling state law right employment article introduction excess benefit plan johnson johnson affiliated companies plan unfunded nonqualified deferred compensation arrangement purpose plan restore retirement benefits eligible participants beneficiaries eligible participants whose benefits consolidated retirement plan johnson johnson crp johnson johnson retirement plan puerto rico employees pr plan referred qualified plan reduced limitations imposed code section limit annual benefits code section compensation limit similar laws puerto rico internal revenue code amended plan initially effective january subsequently amended time time including comply requirements code section reflect crps retirement value formula rvp formula reflect spinoff pr plan crp plan amended restated effective january except otherwise provided incorporate prior amendments include certain clarifications participation plan limited select group management highly compensated employees johnson johnson affiliatesarticle ii definitions whenever used herein following terms shall meanings set forth unless otherwise expressly provided herein unless different meaning plainly required context capitalized terms defined herein shall respective meanings set forth plan document qualified plan beneficiary means respect participant person persons entitled receive death benefit payable respect participant plan preretirement death benefits participants beneficiary shall beneficiary designated qualified plan applicable benefit postretirement death benefits available respect benefits accrued fap formula beneficiary shall person persons designated participant connection payment election unless successor beneficiary properly designated accordance procedures established plan administrator amounts payable beneficiary beneficiarys death shall paid beneficiarys estate code means internal revenue code amended controlled group meaning qualified plan crp means consolidated retirement plan johnson johnson effect amended time time employer means johnson johnson controlled group member designated participating employer qualified plan erisa means employee retirement income security act amended fap benefit means participant eligible receive excess fap benefit defined section plan portion participants excess fap benefit exceeds participants grandfathered benefit fap formula means final average pay formula qualified plan grandfathered benefit means participant benefit plan accrued earned vested december determined manner consistent treas reg section participants grandfathered benefit governed terms plan effect october participant means employee employer eligible participate plan pursuant section eligibility whose participation ended provided section period participation payment start date means date payments scheduled begin section time form payment pension benefits committee meaning qualified plan plan means excess benefit plan johnson johnson affiliated companies set forth herein amended time time plan administrator means pension benefits committee designee successor appointed johnson johnson pr plan means johnson johnson retirement plan puerto rico employees effect amended time time qualified plan means crp pr plan applicable rvp formula means retirement value formula qualified plan separation service means participant participants separation service code section statutory limitations means limitations imposed code section amount annual retirement benefits payable employees qualified plans b code section amount annual compensation may taken account qualified plans c pr plan analogous limitations puerto rico internal revenue code amended article iii eligibility participation eligibility individual participant qualified plan shall become participant plan upon either compensation qualified plan exceeds statutory limitation b accruing benefit qualified plan exceeds statutory limitation benefits may paid qualified plan case unless plan administrator determines individual part select group management highly compensated employees period participation individual becomes participant shall continue participant benefit forfeited paid full article iv benefits amount benefits benefit plan based excess amount would payable qualified plan statutory limitations amount actually payable qualified plan benefit may consist excess fap benefit excess rvp benefit determined follows excess fap benefit extent participant accrued qualified plan benefits fap formula amount payable plan excess fap benefit expressed monthly amount equal excess monthly benefit would payable qualified plans fap formula behalf participant commencing payment start date statutory limitations ii monthly benefit actually payable qualified plans fap formula commencing time form without regard participants actual time form payment qualified plan b excess rvp benefit extent participant accrued qualified plan benefits rvp formula amount payable plan excess rvp benefit expressed lump sum equal excess benefit would payable lump sum qualified plans rvp formula behalf participant commencing payment start date statutory limitations ii benefit actually payable qualified plans rvp formula time form without regard participants actual time form payment qualified plan time form payment excess fap benefit participant grandfathered benefit grandfathered benefit shall paid time form participants benefit qualified plan unless form payment authorized plan administrator accordance terms plan effect october participants fap benefit shall paid annuity form prescribed subsection c commencing first day month coincident next following later participants th birthday participants separation service provided however fap benefit former pfizer consumer eligible receive lump sum pfizer plan shall paid lump sum b excess rvp benefit except provided event death participants excess rvp benefit shall paid lump sum first day seventh month participants separation service c annuity form fap benefit unless otherwise elected participant accordance subsection c annuity form participants fap benefit shall single life annuity participant treated married qualified plan payment start date ii actuarially equivalent joint surviving spouse annuity participant treated married qualified plan payment start date participant may elect writing manner times permitted plan administrator receive fap benefit actuarially equivalent annuity form payment available qualified plan level income options provided election satisfies following conditions change form payment complies treas reg section bii ii plan administrator receives participants election payment start date iii participants election complete good order determined plan administrator actuarial equivalence shall determined using assumptions prescribed qualified plan automatic cashout small benefits actuarial present value participants grandfathered benefit fap benefit excess rvp benefit following participants death actuarial present value beneficiarys death benefit less applicable payment start date benefit applicable beneficiarys total benefit shall paid lump sum applicable payment start date purposes rule actuarial present value shall calculated using qualified plans actuarial assumptions small benefit cashouts effect applicable determination date rehired participants participant separation service later rehired employer following rules shall apply participant earned vested benefit plan time first separation service vested benefit participant earned time first separation service shall paid time form participant returned service provided grandfathered benefits shall subject suspension rules effect october additional vested benefit participant earns return service shall paid provided plan upon subsequent separation service death without regard first separation service b participant earned vested benefit plan time first separation service participant returns service employer earns vested benefit return service participants vested benefit plan shall paid provided plan upon subsequent separation service death without regard first separation service c breakinservice rules terms qualified plan shall determine extent service compensation participant earned time first separation service forfeited taken account calculating amount participants benefit plan return service article v vesting benefits plan shall subject vesting conditions apply qualified plan participant separation service benefit qualified plan fully vested benefit shall payable plan respect unvested portion article vi disability death disability participant continues accrue benefits qualified plans disability provisions payment start date required plan payment participants plan benefit shall commence payment start date required plan case benefits fap formula shall calculated based projection statutory limitations qualified plan additional accruals shall paid accrued fap formula participant stops accruing benefits qualified plan b accrued rvp formula annual basis additional disability accruals intended exempt requirements section code reason disability pay treas reg section aa provision shall construed administered consistently intent comply requirements section code providing total benefit plan qualified plan combined value benefit would payable qualified plan statutory limitations death participant dies payment start date prescribed plan benefit payable plan behalf participant shall death benefit section death benefit shall excess death benefit would payable qualified plan statutory limitations actual death benefit payable qualified plan subject following rules fap formula participant treated married qualified plan date death death benefit respect fap formula shall excess prepension survivor annuity would payable qualified plan statutory limitations preretirement survivor annuity actually payable qualified plan time form without regard actual time form payment qualified plan payment shall begin later first day month coincident next following later participants death date participant would attained age purposes plan election waive prepension survivor annuity qualified plan shall disregarded ii participant treated married qualified plan date death death benefit shall payable plan unless participant qualifies month survivor pension qualified plan participant qualifies month survivor pension qualified plan participants beneficiary shall receive corresponding monthly benefit plan commencing first day month coincident next following participants death amount equal excess monthly benefit would payable qualified plan statutory limitations death benefit qualified plan payable monthly basis actual monthly benefit payable qualified plan determined without regard qualified plan provisions requiring payment lump sum form beneficiary dies prior receiving payments remaining payments shall paid secondary beneficiary named participant else designated beneficiarys estate b rvp formula participant dies payment date prescribed section b excess rvp benefit participants excess rvp benefit shall paid beneficiary lump sum first day month coincident next following participants death c actual payment date death benefits payment death benefits may delayed without interest extent plan administrator determines necessary identify beneficiary arrange payment provided payment made december first calendar year starts participants death later date may permitted irs guidance code section article vii unfunded plan plan assets benefits provided plan unfunded obligations johnson johnson nothing contained plan shall require johnson johnson segregate monies general funds create trust make special deposits purchase policies insurance respect obligations johnson johnson elects purchase individual policies insurance one participants help finance obligations plan individual policies proceeds policies shall times remain sole property johnson johnson neither participants whose lives insured beneficiaries shall ownership rights policies insurance tophat plan status plan maintained primarily purpose providing deferred compensation select group management highly compensated employees within meaning erisa sections article viii plan administration plan administrators powers plan administrator shall powers may necessary carry provisions plan without limiting generality foregoing plan administrator shall discretionary authority determine eligibility plan benefits amount payment terms thereof construe interpret plan determine questions arising administration plan plan administrator may time time establish rules administration plan actions plan administrator shall final conclusive binding participants beneficiaries others making claims plan individuals serving capacity plan administrator shall subject individual liability respect plan delegation administrative authority extent permitted applicable law plan administrator may designate persons assist carrying duties may allocate responsibilities one persons designated administrators references plan administrator shall include plan administrators designee unless contrary clearly indicated engaging third parties assist plan administration johnson johnson plan administrator may employ engage agents accountants actuaries counsel experts persons deems necessary desirable connection interpretation administration plan none plan administrator johnson johnson committees officers directors employees shall liable action taken suffered omitted good faith reliance upon advice opinion agent accountant actuary counsel expert action taken suffered omitted shall conclusive upon upon persons interested plan privilege extent plan administrator johnson johnson affiliate committee employee member affiliate representative consults legal counsel connection design administration plan attorneyclient relationship shall exclusively counsel party engaging counsel employee former employee participant beneficiary individual shall party attorneyclient relationship extent individual involved engaging counsel except determined plan administrator johnson johnson party engaging counsel shall preserve rights maintain confidentiality communications advisers including attorneyclient privilege full extent permitted law proof right receive benefits plan administrator delegate may require proof death disability participant former participant beneficiary evidence right person receive plan benefit tax withholding johnson johnson may withhold cause withheld benefits plan taxes amounts johnson johnson determines required law withheld johnson johnson may deduct cause deducted unpaid portion participants beneficiarys benefit tax johnson johnson reasonably determines due respect benefit amount sufficient pay applicable withholding imputed income alternatively johnson johnson may require participant beneficiary remit johnson johnson designee amount sufficient satisfy applicable federal state local income employment tax respect participants benefit johnson johnson may withhold amount compensation regardless amount withheld reported participant beneficiary shall remain responsible times paying federal state local foreign income employment taxes respect benefits plan including taxes imputed income except employers portion employment taxes event shall johnson johnson employee agent johnson johnson liable interest penalty participant beneficiary incurs failing make timely payments tax claims procedures participant beneficiary duly authorized representative believes denied benefit entitled plan referred section claimant may file written request claims administrator designated plan administrator claims administrator setting forth claim claims administrator shall consider resolve claim set forth time response claims administrator shall render decision within days receiving claim provided claims administrator needs additional time period may extended additional days claims administrator shall notify claimant extension expected response date b denial claim denied whole part claims administrator shall notify claimant decision writing setting forth reasons denial ii reference relevant provisions plan denial based iii description explanation additional material information necessary claimant perfect claim iv description plans review procedures time limits applicable procedures including statement claimants right bring civil action erisa section following adverse benefit determination review c request review within days receiving notice claim denial claimant may request writing appeals administrator designated plan administrator appeals administrator review determination claimant may need submit written comments documents records information relating claim upon request free charge claimant shall provided reasonable access copies documents records information relevant benefit determination claimant request review initial determination within day period claimant shall barred challenging determination time respond request review appeals administrator shall render decision within days receiving request review provided appeals administrator needs additional time period may extended additional days appeals administrator shall notify claimant extension reason therefor expected response date appeals administrator needs additional information period reviewing benefit determination shall tolled claimant responds request additional information claimant fails respond claimants response due e full fair review appeals administrators review shall take account comments documents records information submitted claimant relating request review without regard whether information submitted considered initial benefit determination f decision review decisions review shall final binding respect concerned parties appeal denied appeals administrator shall notify claimant decision writing setting forth reasons decision ii reference relevant plan provisions upon adverse determination based iii statement claimant entitled receive upon request free charge reasonable access copies documents records information relevant claimants claim benefits iv statement claimants right bring civil action erisa section limitations forum selection limitations period prescribed qualified plan generally two years claim repudiated forum selection provisions qualified plan shall apply respect claims plan article ix amendment termination amendment termination johnson johnson pension benefits committee reserves right time time time including retroactively deemed necessary appropriate amend terminate whole part provisions plan provided amendment termination shall reduce participants beneficiarys accrued benefit plan understood reduction plan caused corresponding increase amount payable qualified plan shall treated impermissible reduction ii amendment termination shall change time form payment benefits plan manner results tax code section amendment termination qualified plan shall deemed amendment plan shall subject restrictions section even amendment termination affects benefit provided plan payments upon plan termination extent permitted code section benefits accrued plan shall paid upon termination plan payments shall made manner reasonably designed avoid tax code section article x miscellaneous construction purposes plan unless contrary clearly indicated context use masculine gender shall also include within meaning feminine vice versa b use singular shall also include within meaning plural vice versa c word include shall mean include limited reference statute section statute shall reference successor amended statute section regulations guidance general applicability issued thereunder alienation transfer benefits amount payable plan shall subject manner alienation sale transfer assignment pledge encumbrance kind attempt alienate sell transfer assign pledge otherwise encumber benefit whether presently subsequently payable shall void except required law benefit payable plan shall manner subject garnishment attachment execution legal process liable subject debts liability participant beneficiary section compliance plan intended comply requirements code section avoid tax thereunder shall administered construed interpreted consistently intent johnson johnson warrant plan comply code section respect participant respect payment event shall controlled group member director officer employee controlled group member participant member johnson johnson liable additional tax interest penalty incurred participant beneficiary result plans failure satisfy requirements code section result plans failure satisfy requirements applicable tax laws b sixmonth delay notwithstanding provision plan portion specified employees fap excess rvp benefit payable upon separation service shall paid earlier seventh month separation service participants death delay required provision payment shall commence within days delay period ends amounts otherwise would made paid delay period shall included without interest first payment purposes plan specified employee means specified employee described code section aabi determined johnson johnson accordance procedures identifying specified employees c administrative adjustments payment date payment shall treated made date due plan payment made within days specified due date subject sixmonth delay rule described subsection b ii specified due date latest last day calendar year due date occurs b th day third calendar month following specified due date c later date permitted irs guidance general applicability code section actual date payment shall determined plan administrator sole discretion interest shall owed paid respect amount paid deadline prescribed paragraph scriveners error individuals right benefit plan shall determined accordance terms document provided however document shall applied interpreted without regard scriveners error described next following sentence document document plan determination whether scriveners error occurred shall made pension benefits committee exercise best judgment sole discretion based intent settlor plan applicable understanding johnson johnsons intent plan sponsor taking account evidence written oral deems appropriate helpful pension benefits committee authorized correct scriveners error discovers document document plan recovery overpayment plan administrator determines overpayment incorrect payment distribution made participant spouse beneficiary person plan administrator shall take steps deem appropriate relevant facts circumstances recover payments interest without limiting generality foregoing subject requirements code section overpayments repaid associated interest may recovered offset subsequent payments otherwise becoming due plan remedies section shall exclusive address records participant alternate payee shall keep plan administrator informed post office address post office address spouse beneficiary communication statement notice plan administrator designee addressed participant spouse beneficiary alternate payee last post office address filed plan administrator address filed plan administrator last post office address shown employers member controlled groups records shall binding participant spouse beneficiary alternate payee applicable purposes plan controlling state law except extent preempted erisa plan shall construed accordance laws state new jersey without regard conflict law provisions might otherwise point law different jurisdiction right employment nothing contained plan shall construed contract employment johnson johnson affiliates individual suggest create right employee continued employment limit employers right discharge employee time reason without cause exhibit subsidiaries johnson johnson new jersey corporation us international subsidiaries shown january johnson johnson subsidiary entityname subsidiary jurisdiction us subsidiaries acclarent inc delaware actelion pharmaceuticals us inc delaware akros medical inc delaware albany street llc new jersey alza corporation delaware alza land management inc delaware amo development llc delaware amo manufacturing usa llc delaware amo nominee holdings llc delaware amo sales service inc delaware amo spain holdings llc delaware amo uk holdings llc delaware amo us holdings inc delaware amo usa sales holdings inc delaware amo usa llc delaware animas diabetes care llc delaware animas llc delaware animas technologies llc delaware aortx inc delaware aragon pharmaceuticals inc delaware asia pacific holdings llc new jersey atrionix inc california aub holdings llc delaware auris health inc delaware benevir biopharm inc delaware biomedical enterprises inc texas biosense webster inc california calibra medical llc delaware centocor biologics llc pennsylvania centocor research development inc pennsylvania codman shurtleff inc new jersey coherex medical inc delaware company storecom inc new jersey cordis international corporation delaware cotherix inc delaware csats inc washington depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes institute llc delaware depuy synthes products inc delaware depuy synthes sales inc massachusetts depuy synthes inc delaware dutch holding llc delaware ecl llc delaware ethicon endosurgery inc ohioname subsidiary jurisdiction ethicon endosurgery llc delaware ethicon llc delaware ethicon us llc texas ethicon inc new jersey hansen medical international inc delaware hansen medical inc delaware id acquisition corp new jersey innovative surgical solutions llc michigan janssen biopharma inc delaware janssen biotech inc pennsylvania janssen diagnostics llc delaware janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen products lp new jersey janssen research development llc new jersey janssen scientific affairs llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jevco holding inc new jersey jjhc llc delaware jnj international investment llc delaware johnson johnson new jersey johnson johnson middle east inc new jersey johnson johnson consumer inc new jersey johnson johnson enterprise innovation inc delaware johnson johnson finance corporation new jersey johnson johnson gateway llc new jersey johnson johnson health wellness solutions inc michigan johnson johnson health care systems inc new jersey johnson johnson innovation jjdc inc new jersey johnson johnson innovation llc delaware johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson medical devices diagnostics group latin america llc florida johnson johnson se inc new jersey johnson johnson services inc new jersey johnson johnson surgical vision inc delaware johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida jom pharmaceutical services inc delaware mcneil consumer pharmaceuticals co new jersey mcneil healthcare llc delaware mcneil la llc delaware mcneil mmp llc new jersey mcneil nutritionals llc delaware medical device business services inc indiana medical devices diagnostics global services llc delaware medical devices international llc delaware megadyne medical products inc utah mentor partnership holding company llc delaware mentor texas gp llc delaware mentor texas lp delawarename subsidiary jurisdiction mentor worldwide llc delaware micrus endovascular llc delaware middlesex assurance company limited vermont momenta pharmaceuticals inc delaware neostrata company inc delaware netherlands holding company delaware neuravi inc delaware neuwave medical inc delaware novira therapeutics llc delaware nuvera medical inc delaware omj pharmaceuticals inc delaware omrix biopharmaceuticals inc delaware ortho biologics llc delaware ortho biotech holding llc delaware orthomcneil pharmaceutical llc delaware patriot pharmaceuticals llc pennsylvania peninsula pharmaceuticals llc delaware percivia llc delaware princeton laboratories inc delaware pulsar vascular inc delaware regency urban renewal associates new jersey rutan realty llc new jersey scios llc delaware sightbox llc delaware sterilmed inc minnesota sterilmed inc vermont synthes usa products llc delaware synthes usa llc delaware synthes inc delaware taris biomedical llc delaware tearscience inc delaware anspach effort llc florida vision care institute llc florida tibotec llc delaware torax medical inc delaware tristrata incorporated delaware verb surgical inc delaware vogue international llc delaware vogue international trading inc florida wh development company llc georgia zarbee 's inc delawarename subsidiary jurisdiction international subsidiaries dintegrated aps denmark actelion ltd switzerland actelion manufacturing gmbh germany actelion pharmaceuticals australia pty limited australia actelion pharmaceuticals korea ltd korea republic actelion pharmaceuticals ltd switzerland actelion pharmaceuticals mexico sa de cv mexico actelion pharmaceuticals trading shanghai co ltd china actelion pharmaceuticals uk limited united kingdom actelion registration limited united kingdom actelion treasury unlimited company ireland amo hangzhou co ltd china amo shanghai medical devices trading co ltd china amo asia limited hong kong amo australia pty limited australia amo canada company canada amo denmark aps denmark amo france france amo germany gmbh germany amo groningen bv netherlands amo international holdings ireland amo ireland cayman islands amo ireland finance unlimited company ireland amo italy srl italy amo japan kk japan amo manufacturing spain sl spain amo netherlands bv netherlands amo norway norway amo puerto rico manufacturing inc cayman islands amo singapore pte ltd singapore amo switzerland gmbh switzerland amo united kingdom ltd united kingdom amo uppsala ab sweden apsis france backsvalan aktiebolag sweden backsvalan handelsbolag sweden beijing dabao cosmetics co ltd china berna rhein bv netherlands biosense webster israel ltd israel c consumer products denmark aps denmark campusfoyer apotheke gmbh switzerland carlo erba otc srl italy chromagenics bv netherlands cilabo customer marketing co ltd japan ciz labo co ltd japan cilag ag switzerland cilag gmbh international switzerland cilag holding ag switzerland cilag holding treasury unlimited company ireland cilagbiotech sl spain cna development gmbh switzerland colbar lifescience ltd israel cordis de mexico sa de cv mexiconame subsidiary jurisdiction corimmun gmbh germany darlain trading sa uruguay debsvogue corporation proprietary limited south africa depuy france france depuy hellas sa greece depuy international limited united kingdom depuy ireland unlimited company ireland depuy mexico sa de cv mexico depuy synthes gorgan limited ireland depuy synthes leto sarl luxembourg dr cilabo co ltd japan dr cilabo company limited hong kong ees holdings de mexico de rl de cv mexico ees sa de cv mexico eit emerging implant technologies gmbh germany ethicon biosurgery ireland ireland ethicon endosurgery europe gmbh germany ethicon holding sarl switzerland ethicon ireland unlimited company ireland ethicon pr holdings unlimited company ireland ethicon sarl switzerland ethicon women 's health urology sarl switzerland ethnor proprietary limited south africa ethnor del istmo sa panama venezuela bolivarian ethnor farmaceutica sa republic ethnor guatemala sociedad anomina guatemala finsbury development limited united kingdom finsbury instruments limited united kingdom finsbury medical limited united kingdom finsbury orthopaedics international limited united kingdom finsbury orthopaedics limited united kingdom fms future medical system sa switzerland gh biotech holdings limited ireland global investment participation bv netherlands gmed healthcare bv belgium guangzhou bioseal biotech co ltd china hansen medical deutschland gmbh germany hansen medical uk limited united kingdom healthcare services shanghai ltd china innomedic gesellschaft fr innovative medizintechnik und informatik mbh germany innovalens bv netherlands j j company west africa limited nigeria jj pension trustees limited united kingdom jc general services bv belgium janssen alzheimer immunotherapy holding limited ireland janssen biologics ireland limited ireland janssen biologics bv netherlands janssen cilag farmaceutica sa argentina janssen cilag spa italy janssen cilag spa algeria venezuela bolivarian janssen cilag ca republic janssen de mexico de rl de cv mexico janssen development finance unlimited company ireland janssen egypt llc egyptname subsidiary jurisdiction janssen farmaceutica portugal lda portugal janssen group holdings limited ireland janssen holding gmbh switzerland janssen inc canada janssen irish finance company uc ireland janssen korea ltd korea republic janssen pharmaceutica proprietary limited south africa janssen pharmaceutica nv belgium janssen pharmaceutica sa peru janssen pharmaceutical ireland janssen pharmaceutical kk japan janssen pharmaceutical sciences unlimited company ireland janssen rd ireland ireland janssen sciences ireland unlimited company ireland janssen vaccines prevention bv netherlands janssen vaccines corp korea republic janssencilag france janssencilag new zealand limited new zealand janssencilag denmark janssencilag ag switzerland janssencilag aktiebolag sweden janssencilag norway janssencilag bv netherlands janssencilag de mexico de rl de cv mexico janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag international nv belgium janssencilag kft hungary janssencilag limited thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greece janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa colombia janssencilag sro czech republic janssencilag sa spain janssencilag sa de cv mexico janssenpharma sl spain jc health care ltd israel jj surgical vision spain sl spain jjc acquisition company bv netherlands jjsv belgium bv belgium jjsv manufacturing malaysia sdn bhd malaysia jjsv norden ab sweden jjsv produtos oticos ltda brazil jnj global business services sro czech republic jnj holding emea bv netherlands jnj irish investments ulc canada johnson johnson societa ' per azioni italy johnson johnson angola limitada angolaname subsidiary jurisdiction johnson johnson china investment ltd china johnson johnson egypt sae egypt johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson jamaica limited jamaica johnson johnson kenya limited kenya johnson johnson mozambique limitada mozambique johnson johnson namibia proprietary limited namibia johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson private limited zimbabwe johnson johnson thailand ltd thailand johnson johnson trinidad limited trinidad tobago johnson johnson vietnam co ltd vietnam johnson johnson ab sweden johnson johnson ag switzerland johnson johnson belgium finance company bv belgium johnson johnson bulgaria eood bulgaria johnson johnson china ltd china johnson johnson consumer hong kong limited hong kong johnson johnson consumer thailand limited thailand johnson johnson consumer bv netherlands johnson johnson consumer holdings france france johnson johnson consumer nv belgium johnson johnson consumer saudi arabia limited saudi arabia johnson johnson consumer services eame ltd united kingdom johnson johnson doo slovenia johnson johnson de argentina sac e argentina johnson johnson de chile limitada chile johnson johnson de chile sa chile johnson johnson de colombia sa colombia johnson johnson de costa rica sa costa rica johnson johnson de mexico sa de cv mexico johnson johnson de uruguay sa uruguay venezuela bolivarian johnson johnson de venezuela sa republic johnson johnson del ecuador sa ecuador johnson johnson del paraguay sa paraguay johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson dominicana sas dominican republic johnson johnson european treasury company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson export import llc egypt johnson johnson foundation scotland nonprofit united kingdom johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson guatemala sa guatemala johnson johnson hellas commercial industrial sa greece johnson johnson hellas consumer products commercial societe anonyme greece johnson johnson hemisferica sa puerto rico johnson johnson holding gmbh germany johnson johnson holdings kk japan johnson johnson inc canadaname subsidiary jurisdiction johnson johnson industrial ltda brazil johnson johnson innovation limited united kingdom johnson johnson international singapore pte ltd singapore johnson johnson international financial services company ireland johnson johnson kk japan johnson johnson kft hungary johnson johnson korea ltd korea republic johnson johnson korea selling distribution llc korea republic johnson johnson limitada portugal johnson johnson limited united kingdom johnson johnson llc russian federation johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical proprietary ltd south africa johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical bv netherlands johnson johnson medical gmbh germany johnson johnson medical korea ltd korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson medical sas france johnson johnson medical saudi arabia limited saudi arabia johnson johnson medical servicios profesionales de rl de cv mexico johnson johnson medical taiwan ltd taiwan venezuela bolivarian johnson johnson medical scs republic johnson johnson medikal sanayi ticaret limited sirketi turkey johnson johnson middle east fzllc united arab emirates johnson johnson morocco societe anonyme morocco johnson johnson nordic ab sweden johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson panama sa panama johnson johnson personal care chile sa chile johnson johnson poland sp z oo poland johnson johnson private limited india johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty ltd australia johnson johnson romania srl romania johnson johnson se doo croatia johnson johnson sante beaute france france johnson johnson sdn bhd malaysia johnson johnson servicios corporativos de rl de cv mexico johnson johnson surgical vision india private limited india johnson johnson taiwan ltd taiwan johnson johnson uk treasury company limited united kingdom johnson johnson ukraine llc ukrainename subsidiary jurisdiction johnson johnson vision care shanghai ltd china johnson johnson vision care ireland unlimited company ireland johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson proprietary limited south africa johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey la concha land investment corporation philippines latam international investment company unlimited company ireland lifescan france mcneil ab sweden mcneil denmark aps denmark mcneil healthcare ireland limited ireland mcneil healthcare uk limited united kingdom mcneil iberica slu spain mcneil panama llc panama mcneil products limited united kingdom mcneil sweden ab sweden mds co ltd japan medical industrial brasil ltda brazil medos international sarl switzerland medos sarl switzerland menlo care de mexico sa de cv mexico mentor bv netherlands mentor deutschland gmbh germany mentor medical systems bv netherlands momenta ireland limited ireland neostrata ug haftungsbeschrnkt germany neuravi limited ireland obtech medical mexico sa de cv mexico obtech medical sarl switzerland ogx beauty au pty ltd australia ogx beauty limited united kingdom omj holding gmbh switzerland omj ireland unlimited company ireland omrix biopharmaceuticals ltd israel omrix biopharmaceuticals nv belgium orthotaxy france penta pty limited australia perouse plastie france pharmadirect ltd canada pharmedica laboratories proprietary limited south africa pmc holdings gk japan productos de cuidado personal de la salud de bolivia srl bolivia proleader sa uruguay pt integrated healthcare indonesia indonesia pt johnson johnson indonesia indonesia respivert ltd united kingdom roc international luxembourg sedona enterprise co ltd japan sedona singapore international pte ltd singapore sedona thai international co ltd thailand serhum sa de cv mexiconame subsidiary jurisdiction shanghai elsker mother baby co ltd china shanghai johnson johnson ltd china shanghai johnson johnson pharmaceuticals ltd china sodiac esv belgium spectrum vision limited liability company russian federation spectrum vision limited liability company ukraine spectrum vision limited liability partnership kazakhstan spine solutions gmbh germany surgical process institute deutschland gmbh germany synthes costa rica scr limitada costa rica synthes gmbh germany synthes gmbh switzerland synthes holding ag switzerland synthes holding limited united arab emirates synthes medical immobilien gmbh germany synthes medical surgical equipment instruments trading llc united arab emirates synthes produktions gmbh switzerland synthes proprietary limited south africa synthes smp de rl de cv mexico synthes tuttlingen gmbh germany uab johnson johnson lithuania vania expansion france vision care finance unlimited company ireland xian janssen pharmaceutical ltd china xo limited united kingdomexhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form nos form johnson johnson report dated february relating financial statements effectiveness internal control financial reporting appears pricewaterhousecoopers llp florham park new jersey february exhibit certification chief executive officer pursuant section sarbanesoxley act alex gorsky certify reviewed annual report fiscal year ended january report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting alex gorsky alex gorsky chief executive officer date february exhibit certification chief financial officer pursuant section sarbanesoxley act joseph j wolk certify reviewed annual report fiscal year ended january report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting joseph j wolk joseph j wolk chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned alex gorsky chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended january report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company alex gorsky alex gorsky chief executive officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit certification chief financial officer pursuant section sarbanesoxley act undersigned joseph j wolk chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended january report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company joseph j wolk joseph j wolk chief financial officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability section